{"content":"<li class=\"n-box-item date-title\" data-end=\"1501559999\" data-start=\"1501473600\" data-txt=\"Monday, December 23, 2019\">Monday, July 31, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3283567\" data-ts=\"1501549580\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVTA\" target=\"_blank\">NVTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283567-invitae-secures-74_5m-private-capital-raise-to-support-growth-plans-revenue-up-39-in-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Invitae secures $74.5M private capital raise to support growth plans; revenue up 39% in Q2; shares ahead 8% after hours</a></h4><ul><li>Invitae (NYSE:<a href='https://seekingalpha.com/symbol/NVTA' title='Invitae'>NVTA</a>) inks an <a href=\"https://seekingalpha.com/pr/16901664-invitae-announces-73_5-million-private-placement-offering-fuel-strategic-growth-opportunities\" target=\"_blank\">agreement </a>to sell $73.5M of common stock in a private placement led by existing investors. Net proceeds will be used for general corporate purposes, including funding acquisitions and expanding its menu of tests.</li><li>Under the terms of the agreement, investors will purchase 8,647,058 shares of common stock at $8.50 per share. Preferred shares will be issued to certain existing shareholders. Closing date is August 3.</li><li>On a preliminary basis, Q2 revenue was $14.3M, up 39%. Total number of tests processed was greater than 30,400, up 157%.</li><li>Shares are up&nbsp;<font color='green'>8%</font>&nbsp;after hours on light volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3283566-invitae-buys-combimatrix-good-start-genetics-total-72m-cash-stock-combimatrix-51-percent\" target=\"_blank\">Invitae buys CombiMatrix and Good Start Genetics for a total of ~$72M in cash and stock; CombiMatrix up 51% after hours</a> (July 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3283567\" data-linked=\"Invitae secures $74.5M private capital raise to support growth plans; revenue up 39% in Q2; shares ahead 8% after hours\" data-tweet=\"$NVTA - Invitae secures $74.5M private capital raise to support growth plans; revenue up 39% in Q2; shares ahead 8% after hours https://seekingalpha.com/news/3283567-invitae-secures-74_5m-private-capital-raise-to-support-growth-plans-revenue-up-39-in-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3283567-invitae-secures-74_5m-private-capital-raise-to-support-growth-plans-revenue-up-39-in-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283566\" data-ts=\"1501548878\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVTA\" target=\"_blank\">NVTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283566-invitae-buys-combimatrix-and-good-start-genetics-for-total-of-72m-in-cash-and-stock\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Invitae buys CombiMatrix and Good Start Genetics for a total of ~$72M in cash and stock; CombiMatrix up 51% after hours</a></h4><ul><li>Invitae (NYSE:<a href='https://seekingalpha.com/symbol/NVTA' title='Invitae'>NVTA</a>) inks <a href=\"https://seekingalpha.com/pr/16901668-invitae-acquiring-good-start-genetics-combimatrix-adding-comprehensive-reproductive-health\" target=\"_blank\">two agreements</a> to acquire Good Start Genetics and CombiMatrix (NASDAQ:<a href='https://seekingalpha.com/symbol/CBMX' title='CombiMatrix Corporation'>CBMX</a>) for a total of ~$72M in cash and stock.</li><li>It will acquire privately held Good Start, a molecular diagnostics firm specializing in preimplantation and carrier screening for inherited disorders, for 1.65M shares of NVTA common stock, ~$18.3M in cash to settle its outstanding secured debt and ~$6M in pre-closing and closing-related liabilities and obligations. The deal should close in early August.</li><li>It will <a href=\"https://seekingalpha.com/pr/16901670-combimatrix-enters-merger-agreement-invitae-corporation-acquired-33-million-invitae-common\" target=\"_blank\">acquire CombiMatrix</a>, a family health molecular diagnostics firm specializing in DNA-based reproductive health and pediatric testing services, in al all-stock transaction valued at ~$33M (based on an Invitae share price of $9.49) subject to adjustments. It estimates that the per-share price actually received by CBMX shareholders will be between $8.00 and $8.65. The deal also includes an exchange offer in which holders of CBMX Series F warrants will be offered ~$6M of Invitae common, contingent on 90% of the warrant holders accepting the offer. If less than 90% are on board, Invitae may elect to terminate the merger. The deal should close in Q4.</li><li>Invitae will host a webinar and conference call tomorrow morning, August 1, at 8:00 am ET to discuss the transactions.</li><li>In after hours trading, NVTA is up&nbsp;<font color='green'>8%&nbsp;</font>on light volume and CBMX is up&nbsp;<font color='green'>51%</font>&nbsp;on heavy volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3283566\" data-linked=\"Invitae buys CombiMatrix and Good Start Genetics for a total of ~$72M in cash and stock; CombiMatrix up 51% after hours\" data-tweet=\"$NVTA $NVTA $CBMX - Invitae buys CombiMatrix and Good Start Genetics for a total of ~$72M in cash and stock; CombiMatrix up 51% after hours https://seekingalpha.com/news/3283566-invitae-buys-combimatrix-and-good-start-genetics-for-total-of-72m-in-cash-and-stock?source=tweet\" data-url=\"https://seekingalpha.com/news/3283566-invitae-buys-combimatrix-and-good-start-genetics-for-total-of-72m-in-cash-and-stock\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283560\" data-ts=\"1501539998\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRWI\" target=\"_blank\">DRWI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283560-dragonwaveminus-72-suspended-from-trading-amid-receivership-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DragonWave -72%, suspended from trading amid receivership plan</a></h4><ul>   <li>DragonWave (<a href=\"http://seekingalpha.com/symbol/DRWI\" target=\"_blank\">DRWI</a> <font color='red'>-71.9%</font>) -- whose stock started the year at $2.60 and has since slid to $0.25/share -- says its lenders have filed an application to have KSV Kofman <a href=\"https://seekingalpha.com/pr/16900395-dragonwave-announces-receipt-application-appoint-receiver-tsx-delisting-review\" target=\"_blank\">appointed as receiver</a> over its business and assets.</li>    <li>The Toronto Stock Exchange is reviewing the company's eligibility for continued listing, on criteria of insolvency and financial condition and/or operating results.</li>    <li>That means suspended trading \"until further notice.\" Nasdaq has suspended trading and intends to delist the company on Wednesday.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283560\" data-linked=\"DragonWave -72%, suspended from trading amid receivership plan\" data-tweet=\"$DRWI - DragonWave -72%, suspended from trading amid receivership plan https://seekingalpha.com/news/3283560-dragonwaveminus-72-suspended-from-trading-amid-receivership-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3283560-dragonwaveminus-72-suspended-from-trading-amid-receivership-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283559\" data-ts=\"1501539863\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIMO\" target=\"_blank\">SIMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283559-silicon-motion-shares-down-5-after-revenue-guidance-misses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Silicon Motion shares down 5% after revenue, guidance misses</a></h4><ul><li>        Silicon Motion Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/SIMO' title='Silicon Motion Technology Corporation'>SIMO</a>) reports Q2 results with in-line EPS and revenue miss. Mobile Storage sales were down 6% on the year to $121.6M. Mobile Communications sales were up nearly 8% to $10M. The remaining Others segment fell from $1.5M in last year&rsquo;s quarter to $1.2M.</li><li>                  Cash and equivalents were $306M at the end of the quarter. Bank loans amounted to $25M. Capital expenditures were $2.1M and dividend payments $7.1M.    </li><li>               Q3 guidance includes revenue between $122M and $129M compared to $147.04M consensus. Gross margin expected from 45% to 47% and operating margin from 19% to 21%.&nbsp;</li><li>               FY17 guidance has revenue between $512M to $528M, which would indicate an 8% to 5% drop on the year. Consensus estimates put revenue at $558.86M FY operating margin comes in at 47.5% to 49% with operating margin at 22% to 24%.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16901754-silicon-motion-announces-results-period-ended-june-30-2017\" target=\"_blank\">Press release</a>&nbsp;</li><li>Silicon Motion shares are&nbsp;<font color='red'>down 5.13%</font>&nbsp;aftermarket. &nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3283553-silicon-motion-technology-eps-line-misses-revenue\" target=\"_blank\">Silicon Motion Technology EPS in-line, misses on revenue</a> (July 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3283559\" data-linked=\"Silicon Motion shares down 5% after revenue, guidance misses\" data-tweet=\"$SIMO - Silicon Motion shares down 5% after revenue, guidance misses https://seekingalpha.com/news/3283559-silicon-motion-shares-down-5-after-revenue-guidance-misses?source=tweet\" data-url=\"https://seekingalpha.com/news/3283559-silicon-motion-shares-down-5-after-revenue-guidance-misses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283558\" data-ts=\"1501539457\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INVA\" target=\"_blank\">INVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283558-innoviva-announces-175m-convertible-debt-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Innoviva announces $175M convertible debt offering</a></h4><ul>   <li>Innoviva (NASDAQ:<a href='https://seekingalpha.com/symbol/INVA' title='Innoviva, Inc.'>INVA</a>) is <font color='red'>1.6% lower</font> postmarket alongside news of an <a href=\"https://seekingalpha.com/pr/16901746-innoviva-announces-proposed-offering-175-million-convertible-senior-notes\" target=\"_blank\">offering of $175M in debt</a>.</li>    <li>The company will offer that amount in convertible senior notes due 2025. Underwriters will have a 30-day option to buy up to an additional $17.5M in principal.</li>    <li>That's part of a plan to refinance the company's 9% term notes due 2029; it will redeem part of those notes on Aug. 15 with some of the net proceeds of this offering.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283558\" data-linked=\"Innoviva announces $175M convertible debt offering\" data-tweet=\"$INVA - Innoviva announces $175M convertible debt offering https://seekingalpha.com/news/3283558-innoviva-announces-175m-convertible-debt-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3283558-innoviva-announces-175m-convertible-debt-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283555\" data-ts=\"1501538843\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRUB\" target=\"_blank\">GRUB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283555-grubhubplus-3_5-grouponplus-3_2-partner-on-delivery\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GrubHub +3.5%, Groupon +3.2% as they partner on delivery</a></h4><ul>   <li>GrubHub (NYSE:<a href='https://seekingalpha.com/symbol/GRUB' title='GrubHub Inc.'>GRUB</a>) is <font color='green'>up 3.5%</font> after hours, and Groupon (NASDAQ:<a href='https://seekingalpha.com/symbol/GRPN' title='Groupon, Inc.'>GRPN</a>) <font color='green'>up 3.2%</font>, as the two companies set a <a href=\"https://seekingalpha.com/pr/16901501-groupon-grubhub-announce-strategic-partnership-bring-food-delivery-groupon-customers\" target=\"_blank\">strategic partnership on food delivery</a>.</li>    <li>Financial terms weren't disclosed. The deal allows Groupon to offer its users food delivery from GrubHub via Groupon's platform, allowing for them to redeem Groupon deals.</li>    <li>GrubHub is also taking some assets from Groupon in 27 company-owned OrderUp delivery markets, and will manage ordering/delivery in the Groupon To Go markets.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283555\" data-linked=\"GrubHub +3.5%, Groupon +3.2% as they partner on delivery\" data-tweet=\"$GRUB $GRUB $GRPN - GrubHub +3.5%, Groupon +3.2% as they partner on delivery https://seekingalpha.com/news/3283555-grubhubplus-3_5-grouponplus-3_2-partner-on-delivery?source=tweet\" data-url=\"https://seekingalpha.com/news/3283555-grubhubplus-3_5-grouponplus-3_2-partner-on-delivery\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283551\" data-ts=\"1501538384\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCSA\" target=\"_blank\">CMCSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283551-warners-dunkirk-holds-off-animated-emojis-box-office\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Warner&#39;s &#39;Dunkirk&#39; holds off animated emojis at box office</a></h4><ul>   <li>War epic <i>Dunkirk</i> (<a href=\"http://seekingalpha.com/symbol/TWX\" target=\"_blank\">TWX</a> <font color='red'>-0.3%</font>) held off a charge from <i>The Emoji Movie</i> (<a href=\"http://seekingalpha.com/symbol/SNE\" target=\"_blank\">SNE</a> <font color='green'>+0.2%</font>) to lead domestic box office for a second week, and raise its cumulative total over the symbolic $100M mark.</li>    <li>The Warner Bros. film, about the eponymous WWII evacuation, dropped just 47% of its business W/W to draw $26.6M. Meanwhile, with $131.5M in foreign receipts, it brought its worldwide total to $232.8M.</li>    <li>The critically scathed (7% on Rotten Tomatoes) <i>Emoji Movie</i> settled for second place with $24.5M.</li>    <li><i>Girls Trip</i> (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color='green'>+2.4%</font>) settled into third with $19.6M just ahead of another newcome, <i>Atomic Blonde</i> (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>), released by Universal unit Focus Features and drawing $18.3M in its rollout.</li>    <li>The top five was rounded out by <i>Spider Man: Homecoming</i> (NYSE:<a href='https://seekingalpha.com/symbol/SNE' title='Sony Corporation'>SNE</a>), which took $13.3M and brought its domestic total to $278.2M (and worldwide to $633.6M).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283551\" data-linked=\"Warner&#39;s &#39;Dunkirk&#39; holds off animated emojis at box office\" data-tweet=\"$CMCSA $CMCSA $SNE - Warner&#39;s &#39;Dunkirk&#39; holds off animated emojis at box office https://seekingalpha.com/news/3283551-warners-dunkirk-holds-off-animated-emojis-box-office?source=tweet\" data-url=\"https://seekingalpha.com/news/3283551-warners-dunkirk-holds-off-animated-emojis-box-office\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283543\" data-ts=\"1501537064\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMKR\" target=\"_blank\">AMKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283543-amkor-technology-misses-q2-and-guidance-estimates-shares-down-5_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amkor Technology misses Q2 and guidance estimates; shares down 5.5%</a></h4><ul><li>        Amkor Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/AMKR' title='Amkor Technology, Inc.'>AMKR</a>) reports Q2 with revenue and EPS misses. Advanced product sales were up 12.5% on the year to $431M and Mainstream product sales were up 5% to $558M. &nbsp;</li><li>        Notable events: Amkor completed the acquisition of wafer-level packaging company Nanium in May and sold the K1 factory in Korea for $142M, recognized as a $82M after-tax gain.</li><li>        Q3 outlook puts net sales between $1.04B and $1.12B, which represents a year-over-year growth of 5% to 13%. Consensus estimates put revenue at $1.16B. Amkor also expects gross margin of 17% to 20%.</li><li>               <a href=\"https://seekingalpha.com/pr/16901533-amkor-technology-reports-financial-results-second-quarter-2017\" target=\"_blank\">Press release</a>&nbsp;</li><li>               Amkor shares are&nbsp;<font color='red'>down 5.5%</font>&nbsp;aftermarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3283465-amkor-technology-misses-0_09-misses-revenue\" target=\"_blank\">Amkor Technology misses by $0.09, misses on revenue</a> (July 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3283543\" data-linked=\"Amkor Technology misses Q2 and guidance estimates; shares down 5.5%\" data-tweet=\"$AMKR - Amkor Technology misses Q2 and guidance estimates; shares down 5.5% https://seekingalpha.com/news/3283543-amkor-technology-misses-q2-and-guidance-estimates-shares-down-5_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3283543-amkor-technology-misses-q2-and-guidance-estimates-shares-down-5_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283541\" data-ts=\"1501536891\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283541-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/CGNX' title='Cognex Corporation'>CGNX</a> <font color='green'>+8.9%</font>. <a href='https://seekingalpha.com/symbol/ALSN' title='Allison Transmission'>ALSN</a> <font color='green'>+7.1%</font>. HLS <font color='green'>+3.6%</font>. <a href='https://seekingalpha.com/symbol/GRUB' title='GrubHub Inc.'>GRUB</a> <font color='green'>+3.5%</font>. <a href='https://seekingalpha.com/symbol/P' title='Pandora Media'>P</a> <font color='green'>+3.4%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/SND' title='Smart Sand'>SND</a> <font color='red'>-8.3%</font>. <a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='red'>-8.6%</font>. <a href='https://seekingalpha.com/symbol/SLCA' title='U.S. Silica'>SLCA</a> <font color='red'>-8.5%</font>. <a href='https://seekingalpha.com/symbol/NLS' title='Nautilus, Inc.'>NLS</a> <font color='red'>-8.5%</font>. <a href='https://seekingalpha.com/symbol/AMKR' title='Amkor Technology, Inc.'>AMKR</a> <font color='red'>-4.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283541\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$CGNX $ALSN $EHC - After Hours Gainers / Losers https://seekingalpha.com/news/3283541-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3283541-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283530\" data-ts=\"1501535301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WG\" target=\"_blank\">WG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283530-willbros-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Willbros beats by $0.02, beats on revenue</a></h4><ul><li>Willbros (NYSE:<a href='https://seekingalpha.com/symbol/WG' title='Willbros Group, Inc.'>WG</a>): Q2 EPS of -$0.02 <font color='green'>beats by $0.02</font>.</li><li>Revenue of $227.4M (+17.6% Y/Y) <font color='green'>beats by $42.17M</font>.</li><li>Shares <font color='green'>+6.9%</font> AH.</li><li><a href='https://seekingalpha.com/pr/16901684-willbros-reports-improved-second-quarter-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3283530\" data-linked=\"Willbros beats by $0.02, beats on revenue\" data-tweet=\"$WG - Willbros beats by $0.02, beats on revenue https://seekingalpha.com/news/3283530-willbros-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3283530-willbros-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283508\" data-ts=\"1501533468\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGNX\" target=\"_blank\">CGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283508-cognex-beats-q1-estimates-tops-seasonal-slump-shares-up-7_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cognex beats Q1 estimates, tops seasonal slump; shares up 7.8%</a></h4><ul><li>        Cognex (NASDAQ:<a href='https://seekingalpha.com/symbol/CGNX' title='Cognex Corporation'>CGNX</a>) reports Q1 earnings with revenue and EPS beats. &nbsp;Revenue increased 40% on the year and 4% sequentially, which are notable growths considering the company typically has a seasonal dip between Q4 and Q1.</li><li>               Gross margin was 79% for Q1 and Q4 compared to 78% for last year&rsquo;s quarter with the year-on-year increase attributed to cost efficiencies due to the higher sales.&nbsp;</li><li>               RD&amp;E expenses were also up 11% on the year and 17% on the quarter due to employee costs partially due to acquisition-related hires.&nbsp;</li><li>               Cognex ended the quarter with $781M in cash and investments with no debt.&nbsp;</li><li>               Q2 outlook: revenue between $165M and $170M compared to $169.8 consensus. Gross margin expected in mid-to-high 70% range and operating expenses could go up 10% due to growth activities and acquisition activities.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16816632-cognex-reports-record-first-quarter-results-revenue-net-income-earnings-per-share\" target=\"_blank\">Press release</a>&nbsp;</li><li>               Cognex shares are&nbsp;<font color='green'>up 7.83%&nbsp;</font>aftermarket.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3283455-cognex-beats-0_02-beats-revenue\" target=\"_blank\">Cognex beats by $0.02, beats on revenue</a> (July 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3283508\" data-linked=\"Cognex beats Q1 estimates, tops seasonal slump; shares up 7.8%\" data-tweet=\"$CGNX - Cognex beats Q1 estimates, tops seasonal slump; shares up 7.8% https://seekingalpha.com/news/3283508-cognex-beats-q1-estimates-tops-seasonal-slump-shares-up-7_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3283508-cognex-beats-q1-estimates-tops-seasonal-slump-shares-up-7_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283506\" data-ts=\"1501533412\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HLIT\" target=\"_blank\">HLIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283506-harmonicminus-4_9-revenues-profits-decline-and-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Harmonic -4.9% as revenues, profits decline and miss</a></h4><ul>   <li>Harmonic (<a href=\"http://seekingalpha.com/symbol/HLIT\" target=\"_blank\">HLIT</a> <font color='green'>+2.5%</font>) has <font color='red'>slipped 4.9%</font> after hours following <a href=\"https://seekingalpha.com/news/3283451-harmonic-misses-0_04-misses-revenue\" target=\"_blank\">Q2 earnings</a> where revenues fell both sequentially and year-over-year.</li>    <li>Product sales fell by more than third, though the company pointed to growing demand for video infrastructure provided as-a-service.</li>    <li>Bookings fell to $91.1M from a year-ago $117.3M.</li>    <li>Revenue breakout: Product, $50.2M (down 35.2%); Services, $32.1M (down 0.1%).</li>    <li>Cash, equivalents and short-term investments came to $52.9M, down from last quarter's $55.3M.</li>    <li>The company's guiding to Q3 revenue (non-GAAP) of $80M-$90M (light of consensus for $92.8M), gross margin of 51-52%, and EPS of -$0.11 to -$0.03 (below expectations for a per-share profit of $0.02).</li>    <li>For the full year, it sees $336M-$356M in revenue (below $380M consensus), gross margin of 51-51.5% and EPS of -$0.50 to -$0.33 (below expectations for -$0.04).</li>    <li><a href=\"www.harmonicinc.com\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16901491-harmonic-announces-second-quarter-2017-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3283506\" data-linked=\"Harmonic -4.9% as revenues, profits decline and miss\" data-tweet=\"$HLIT - Harmonic -4.9% as revenues, profits decline and miss https://seekingalpha.com/news/3283506-harmonicminus-4_9-revenues-profits-decline-and-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3283506-harmonicminus-4_9-revenues-profits-decline-and-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283492\" data-ts=\"1501532739\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EHC\" target=\"_blank\">EHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283492-healthsouth-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HealthSouth beats by $0.03, beats on revenue</a></h4><ul><li>HealthSouth (HLS): Q2 EPS of $0.71 <font color='green'>beats by $0.03</font>.</li><li>Revenue of $981.3M (+6.6% Y/Y) <font color='green'>beats by $7.73M</font>.</li><li>Shares <font color='green'>+5.5%</font>.</li><li><a href='https://seekingalpha.com/pr/16901589-healthsouth-reports-results-second-quarter-2017-updates-full-year-2017-guidance'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3283492\" data-linked=\"HealthSouth beats by $0.03, beats on revenue\" data-tweet=\"$EHC - HealthSouth beats by $0.03, beats on revenue https://seekingalpha.com/news/3283492-healthsouth-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3283492-healthsouth-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283471\" data-ts=\"1501531968\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TXRH\" target=\"_blank\">TXRH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283471-post-earnings-pop-for-texas-roadhouse\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Post-earnings pop for Texas Roadhouse</a></h4><ul>     <li>Shares of Texas Roadhouse (NASDAQ:<a href='https://seekingalpha.com/symbol/TXRH' title='Texas Roadhouse, Inc.'>TXRH</a>) pop after the company reports that comparable restaurant sales rose  4.0% at company-owned restaurants in Q2 and 3.6% at domestic franchise outlets. Both marks were ahead of consensus estimates.</li><li>Wage inflation led to a 28 bp decline in adjusted restaurant margin to 18.9% of sales during the quarter.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3283447-texas-roadhouse-eps-line-beats-revenue\" target=\"_blank\">Texas Roadhouse EPS in-line, beats on revenue</a> (July 31)</li><li>TXRH&nbsp;<font color='green'>+6.87%</font>&nbsp;AH to $50.55.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283471\" data-linked=\"Post-earnings pop for Texas Roadhouse\" data-tweet=\"$TXRH - Post-earnings pop for Texas Roadhouse https://seekingalpha.com/news/3283471-post-earnings-pop-for-texas-roadhouse?source=tweet\" data-url=\"https://seekingalpha.com/news/3283471-post-earnings-pop-for-texas-roadhouse\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283470\" data-ts=\"1501531942\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/P\" target=\"_blank\">P</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283470-pandora-mediaplus-3_8-q2-beat-shows-broad-revenue-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pandora Media +3.8% as Q2 beat shows broad revenue gains</a></h4><ul>   <li>Pandora Media (<a href=\"http://seekingalpha.com/symbol/P\" target=\"_blank\">P</a> <font color='red'>-5.5%</font>) is <font color='green'>up 3.8%</font> after hours, following <a href=\"https://seekingalpha.com/news/3283443-pandora-media-beats-0_03-beats-revenue\" target=\"_blank\">Q2 earnings</a> where it grew core ad revenues and yet boosted subscription sales and revenues from its smaller ticketing service.</li>    <li>Listener hours (\"actively managed this quarter to optimize profitability in our ad-supported service\") fell to 5.22B from a year-ago 5.66B. Active listeners totaled 76M.</li>    <li>Advertising RPM rose to $66.15 from $53.34; LPM rose to $35.84 from $30.65.</li>    <li>In new measures, subscription ARPU was $4.82; subscription LPU was $3.11.</li>    <li>Revenue breakout: Advertising, $278.2M (up 4.9%); Subscription and other, $68.9M (up 25%); Ticketing service, $29.7M (up 30.6%).</li>    <li><a href=\"http://investor.pandora.com\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16901487-pandora-reports-q2-2017-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3283470\" data-linked=\"Pandora Media +3.8% as Q2 beat shows broad revenue gains\" data-tweet=\"$P - Pandora Media +3.8% as Q2 beat shows broad revenue gains https://seekingalpha.com/news/3283470-pandora-mediaplus-3_8-q2-beat-shows-broad-revenue-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/3283470-pandora-mediaplus-3_8-q2-beat-shows-broad-revenue-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283452\" data-ts=\"1501531582\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALSN\" target=\"_blank\">ALSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283452-allison-transmission-beats-0_16-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allison Transmission beats by $0.16, beats on revenue</a></h4><ul><li>Allison Transmission (NYSE:<a href='https://seekingalpha.com/symbol/ALSN' title='Allison Transmission'>ALSN</a>): Q2 EPS of $0.63 <font color='green'>beats by $0.16</font>.</li><li>Revenue of $580M (+22.1% Y/Y) <font color='green'>beats by $68.23M</font>.</li><li>Shares <font color='green'>+4.6%</font>.</li><li><a href='https://seekingalpha.com/pr/16901480-allison-transmission-announces-second-quarter-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3283452\" data-linked=\"Allison Transmission beats by $0.16, beats on revenue\" data-tweet=\"$ALSN - Allison Transmission beats by $0.16, beats on revenue https://seekingalpha.com/news/3283452-allison-transmission-beats-0_16-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3283452-allison-transmission-beats-0_16-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283447\" data-ts=\"1501531496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TXRH\" target=\"_blank\">TXRH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283447-texas-roadhouse-eps-in-line-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Texas Roadhouse EPS in-line, beats on revenue</a></h4><ul><li>Texas Roadhouse (NASDAQ:<a href='https://seekingalpha.com/symbol/TXRH' title='Texas Roadhouse, Inc.'>TXRH</a>): Q2 EPS of $0.53 in-line.</li><li>Revenue of $566.3M (+11.3% Y/Y) <font color='green'>beats by $3.04M</font>.</li><li>Shares <font color='green'>+5.4%</font>.</li><li><a href='https://seekingalpha.com/pr/16901490-texas-roadhouse-inc-announces-second-quarter-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3283447\" data-linked=\"Texas Roadhouse EPS in-line, beats on revenue\" data-tweet=\"$TXRH - Texas Roadhouse EPS in-line, beats on revenue https://seekingalpha.com/news/3283447-texas-roadhouse-eps-in-line-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3283447-texas-roadhouse-eps-in-line-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283443\" data-ts=\"1501531412\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/P\" target=\"_blank\">P</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283443-pandora-media-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pandora Media beats by $0.03, beats on revenue</a></h4><ul><li>Pandora Media (NYSE:<a href='https://seekingalpha.com/symbol/P' title='Pandora Media'>P</a>): Q2 EPS of -$0.21 <font color='green'>beats by $0.03</font>.</li><li>Revenue of $376.8M (+9.8% Y/Y) <font color='green'>beats by $7.93M</font>.</li><li>Shares <font color='green'>+3.5%</font>.</li><li><a href='https://seekingalpha.com/pr/16901487-pandora-reports-q2-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3283443\" data-linked=\"Pandora Media beats by $0.03, beats on revenue\" data-tweet=\"$P - Pandora Media beats by $0.03, beats on revenue https://seekingalpha.com/news/3283443-pandora-media-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3283443-pandora-media-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283448\" data-ts=\"1501531129\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVA\" target=\"_blank\">CVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283448-covanta-upped-to-buy-bmo-path-opened-to-improved-free-cash-flow\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Covanta upped to Buy at BMO as path opened to improved free cash flow</a></h4><ul>     <li>Covanta (<a href='https://seekingalpha.com/symbol/CVA' title='Covanta Holding Corporation'>CVA</a> <font color='green'>+5%</font>) is <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/07/9847850/despite-risks-covantas-path-to-improvement-has-become-cl\" target=\"_blank\">upgraded to Buy</a> from Hold with a $17 price target, raised from $15.50, at Stifel, which says YTD results and strong dynamics in the waste to energy market brightens CVA's path to improved free cash flow.</li>     <li>BMO notes CVA's Q2 revenues and adjusted EBITDA beat expectations, with waste and services revenue growth offsetting declines in energy and recycle metals, adding that the revenue beat came despite a $15M revenue loss due to delay in return to service following a February fire at its Fairfax facility; the firm also believes CVA's Y/Y decline in free cash flow was more of a timing issue related to scheduled projects.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3283448\" data-linked=\"Covanta upped to Buy at BMO as path opened to improved free cash flow\" data-tweet=\"$CVA - Covanta upped to Buy at BMO as path opened to improved free cash flow https://seekingalpha.com/news/3283448-covanta-upped-to-buy-bmo-path-opened-to-improved-free-cash-flow?source=tweet\" data-url=\"https://seekingalpha.com/news/3283448-covanta-upped-to-buy-bmo-path-opened-to-improved-free-cash-flow\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283437\" data-ts=\"1501531048\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KTOV\" target=\"_blank\">KTOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283437-kitov-submits-u-s-marketing-application-for-lead-candidate-kitminus-302-shares-down-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kitov submits U.S. marketing application for lead candidate KIT-302; shares down 3%</a></h4><ul><li>Kitov Pharmaceuticals Holdings (<a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='red'>-3.1%</font>) <a href=\"https://seekingalpha.com/pr/16901435-kitov-submits-new-drug-application-fda-kitminus-302\" target=\"_blank\">files a New Drug Application</a> &#40;NDA&#41; with the FDA seeking approval for KIT-302 for the simultaneous treatment of osteoarthritis pain and hypertension. An action date will be assigned after the agency formally accepts the filing for review.</li><li><a href=\"http://kitovpharma.com/products-2/kit-302/\" target=\"_blank\">KIT-302</a>&nbsp;is a combination drug that treats osteoporosis-related pain (celecoxib, branded as&nbsp;<a href=\"http://www.celebrex.com/?source=google&amp;HBX_PK=s_celebrex&amp;o=23040695|165564013|0&amp;skwid=43700007994682827&amp;sourcepoint=BS\" target=\"_blank\">Celebrex</a>&nbsp;by Pfizer) and hypertension (amlodipine besylate, branded as&nbsp;<a href=\"http://labeling.pfizer.com/ShowLabeling.aspx?id=562\" target=\"_blank\">Norvasc</a>).</li><li>Investors appear to be \"selling on the news\" since shares ran up 85% before the announcement.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3229123-kitov-pharma-announces-completion-testing-kitminus-302-u-s-marketing-application-tap-q1\" target=\"_blank\">Kitov Pharma announces the completion of testing on KIT-302, U.S. marketing application on tap for Q1</a> (Dec. 7, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3283437\" data-linked=\"Kitov submits U.S. marketing application for lead candidate KIT-302; shares down 3%\" data-tweet=\"$KTOV - Kitov submits U.S. marketing application for lead candidate KIT-302; shares down 3% https://seekingalpha.com/news/3283437-kitov-submits-u-s-marketing-application-for-lead-candidate-kitminus-302-shares-down-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3283437-kitov-submits-u-s-marketing-application-for-lead-candidate-kitminus-302-shares-down-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283436\" data-ts=\"1501530546\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGO\" target=\"_blank\">EGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283436-eldorado-gold-downgraded-credit-suisse-for-second-time-in-month\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eldorado Gold downgraded at Credit Suisse for second time in a month</a></h4><ul>     <li>Eldorado Gold (<a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a> <font color='red'>-6.6%</font>) plunges after Credit Suisse <a href=\"http://www.barrons.com/articles/3-reasons-why-eldorado-gold-isnt-panning-out-1501507796\" target=\"_blank\">downgrades</a> shares to Underperform from Neutral with a $2.40 price target, cut from $2.25, at Credit Suisse, just a month after an earlier downgrade at the firm.</li>     <li>Credit Suisse cites continued setbacks in Greece, another re-assessment of timelines and capital plans in Greece in light of ongoing challenges, and prolonged negative free cash flow until 2021 if Skouries is built, or 2018 positive free cash flow of ~$100M but a reduced net asset value estimate if the mine is suspended.</li>     <li>EGO issued a second guidance downgrade due to the Olympias tailings filter issue, now forecasting 290K-340K oz. in 2017 at $900/oz all-in sustained cost from its earlier view of 365K-400K oz. at $845-$875/oz. in early 2017; Credit Suisse's new estimate is 301K oz. at $894/oz. from its earlier 343K oz. at $855/oz.</li></ul><div class=\"tiny-share-widget\" data-id=\"3283436\" data-linked=\"Eldorado Gold downgraded at Credit Suisse for second time in a month\" data-tweet=\"$EGO - Eldorado Gold downgraded at Credit Suisse for second time in a month https://seekingalpha.com/news/3283436-eldorado-gold-downgraded-credit-suisse-for-second-time-in-month?source=tweet\" data-url=\"https://seekingalpha.com/news/3283436-eldorado-gold-downgraded-credit-suisse-for-second-time-in-month\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283433\" data-ts=\"1501529558\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSTI\" target=\"_blank\">SSTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283433-imperial-capital-seesplus-30-upside-for-shotspotter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Imperial Capital sees +30% upside for Shotspotter</a></h4><ul>     <li>Imperial Capital launches coverage on Shotspotter (<a href='https://seekingalpha.com/symbol/SSTI' title='ShotSpotter'>SSTI</a> <font color='green'>+0.1%</font>)&nbsp;with an Outperform rating and a price target of $16.</li>     <li>The firm expects Shotspotter's revenue to grow at a 35% clip annually over the next three years.</li><li>Shotspotter trades on the low end of its post-IPO range.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283433\" data-linked=\"Imperial Capital sees +30% upside for Shotspotter\" data-tweet=\"$SSTI - Imperial Capital sees +30% upside for Shotspotter https://seekingalpha.com/news/3283433-imperial-capital-seesplus-30-upside-for-shotspotter?source=tweet\" data-url=\"https://seekingalpha.com/news/3283433-imperial-capital-seesplus-30-upside-for-shotspotter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283426\" data-ts=\"1501527554\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DO\" target=\"_blank\">DO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283426-diamond-offshoreplus-3-after-strong-q2-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Diamond Offshore +3% after strong Q2 earnings beat</a></h4><ul>     <li>Diamond Offshore Drilling (<a href='https://seekingalpha.com/symbol/DO' title='Diamond Offshore Drilling Inc.'>DO</a> <font color='green'>+3.3%</font>) enjoys strong gains after easily beating <a href=\"https://seekingalpha.com/news/3283212-diamond-offshore-drilling-beats-0_21-beats-revenue\" target=\"_blank\">Q2 earnings</a> expectations, boosted by higher utilization in the ultra-deep and deepwater segments.</li><li>Q2 revenues in DO's ultra-deepwater segment rose 16% Q/Q in Q2, representing 72% of total  drilling revenues vs. 67% in Q1, with utilization of  59% vs. Q1's 50% but at a  slightly lower dayrate of $436K.</li><li>DO says its contracted backlog as of June 30 was $2.9B.</li>     <li>Additionally, DO says it <a href=\"http://www.offshoreenergytoday.com/diamond-stacks-one-plans-to-sell-five-semi-sub-rigs/\" target=\"_blank\">stacked one semi-sub rig</a> and is selling five others, according to its latest fleet status report; the Ocean Victory reportedly was stacked after working for BP offshore Trinidad and Tobago under a two-year term which  ended in May at a dayrate of $398K.</li></ul><div class=\"tiny-share-widget\" data-id=\"3283426\" data-linked=\"Diamond Offshore +3% after strong Q2 earnings beat\" data-tweet=\"$DO - Diamond Offshore +3% after strong Q2 earnings beat https://seekingalpha.com/news/3283426-diamond-offshoreplus-3-after-strong-q2-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3283426-diamond-offshoreplus-3-after-strong-q2-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283423\" data-ts=\"1501526458\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283423-technology-top-gainers-losers-of-2-40-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:40 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SOHU' title='Sohu.com Inc.'>SOHU</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/DGII' title='Digi International Inc.'>DGII</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/SCKT' title='Socket Mobile, Inc.'>SCKT</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ELSE' title='Electro-Sensors, Inc.'>ELSE</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CYBE' title='CyberOptics Corporation'>CYBE</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/IDN' title='Intellicheck Mobilisa, Inc.'>IDN</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/QBAK' title='Qualstar Corporation'>QBAK</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/MRAM' title='Everspin Technologies'>MRAM</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283423\" data-linked=\"Technology - Top Gainers / Losers as of 2:40 pm\" data-tweet=\"$SOHU $DGII $SCKT - Technology - Top Gainers / Losers as of 2:40 pm https://seekingalpha.com/news/3283423-technology-top-gainers-losers-of-2-40-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3283423-technology-top-gainers-losers-of-2-40-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283421\" data-ts=\"1501526242\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UA\" target=\"_blank\">UA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283421-jefferies-positive-on-under-armour-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies positive on Under Armour ahead of earnings</a></h4><ul>     <li>Jefferies analyst Randal Konik <a href=\"http://www.barrons.com/articles/under-armour-time-to-buy-1501518475\" target=\"_blank\">recommends</a> buying Under Armour (<a href='https://seekingalpha.com/symbol/UA' title='Under Armour, Inc. Class C'>UA</a>, <a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a>) ahead of the company's earnings report.</li>     <li>\"Too much fear/hate has created a dislocation in UAA shares in our view with inventories leaner, Curry 4 on way, huge int&rsquo;l TAM, Kohl's negativity misplaced, easier compares ahead, and strong athletic trends,\" he writes.</li><li>\"Shorts are too aggressive, while the sell-side is not studying risk/reward,\" reasons Konik.</li><li>Under Armour reports earnings tomorrow. SA contributor Brian Gilmartin <a href=\"https://seekingalpha.com/article/4092567-armour-earnings-preview-ua-brand-critical-juncture\" target=\"_blank\">posted</a> a comprehensive earnings preview earlier today.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283421\" data-linked=\"Jefferies positive on Under Armour ahead of earnings\" data-tweet=\"$UA $UA $UAA - Jefferies positive on Under Armour ahead of earnings https://seekingalpha.com/news/3283421-jefferies-positive-on-under-armour-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3283421-jefferies-positive-on-under-armour-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283418\" data-ts=\"1501525456\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FWONA\" target=\"_blank\">FWONA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283418-cnbc-softbank-sticking-to-charter-buyout-pursuit-financing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CNBC: SoftBank sticking to Charter buyout pursuit, has financing</a></h4><ul>   <li>Despite what seems like hourly changes to the story, SoftBank (<a href=\"http://seekingalpha.com/symbol/SFTBY\" target=\"_blank\">SFTBY</a> <font color='red'>-2.9%</font>) isn't letting go of recently plans to take over Charter Communications (<a href=\"http://seekingalpha.com/symbol/CHTR\" target=\"_blank\">CHTR</a> <font color='green'>+5%</font>). The conglomerate has formed a buyout offer and <a href=\"https://www.cnbc.com/2017/07/31/softbank-hasnt-given-up-on-charter-yet-sources-say.html\" target=\"_blank\">has financing lined up</a>, CNBC reports.</li>    <li>That's despite Charter's rebuffing of any merger with SoftBank or Sprint (S -2.8%), the U.S. carrier that it owns.</li>    <li>According to the report, SoftBank would contribute sizable equity to a new company that would offer a premium to Charter and Sprint shareholders. That offer would be 50% cash and 50% shares of the new company.</li>    <li>David Faber reports that SoftBank has financing from three global banks and is comfortable levering up the new firm's balance sheet to 5-6 times EBITDA. But he notes it may be difficult for SoftBank to get near the $500/share mark that would start to interest Charter shareholders, particularly including John Malone's Liberty Media (NASDAQ:<a href='https://seekingalpha.com/symbol/FWONA' title='Liberty Media Corp'>FWONA</a>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3283350-cable-firms-rise-sprint-merger-saga-develops\" target=\"_blank\">Cable firms rise as Sprint merger saga develops</a> (Jul. 31 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3283192-softbank-closes-charter\" target=\"_blank\">Softbank closes in on Charter</a> (Jul. 31 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3283169-wsj-charter-sprint-deal\" target=\"_blank\">WSJ: Charter out of any Sprint deal</a> (Jul. 30 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3283154-wsj-report-sprint-pursuing-full-merger-charter\" target=\"_blank\">WSJ report: Sprint pursuing full merger with Charter</a> (Jul. 28 2017)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3283418\" data-linked=\"CNBC: SoftBank sticking to Charter buyout pursuit, has financing\" data-tweet=\"$FWONA $FWONA $SFTBY - CNBC: SoftBank sticking to Charter buyout pursuit, has financing https://seekingalpha.com/news/3283418-cnbc-softbank-sticking-to-charter-buyout-pursuit-financing?source=tweet\" data-url=\"https://seekingalpha.com/news/3283418-cnbc-softbank-sticking-to-charter-buyout-pursuit-financing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283417\" data-ts=\"1501525357\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NADL\" target=\"_blank\">NADL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283417-seadrill-extends-north-atlantic-drilling-loan-maturity-date\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seadrill extends North Atlantic Drilling loan maturity date</a></h4><ul>     <li>North Atlantic Drilling (<a href='https://seekingalpha.com/symbol/NADL' title='North Atlantic Drilling Ltd.'>NADL</a> <font color='red'>-5.3%</font>) is sharply lower despite gaining more breathing space after securing a <a href=\"http://www.nadlcorp.com/investors/news/news-release?ResultPageURL=http://cws.huginonline.com/N/155697/PR/201707/2124258.xml\" target=\"_blank\">new interim funding agreement</a> with majority shareholder Seadrill (<a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited &#40;New&#41;'>SDRL</a> <font color='red'>-5.1%</font>) while the two companies continue to finalize a financial restructuring plan.</li>     <li>The revised funding agreement extends the expiration date of the $150M credit facility from July 31 until Sept. 12.</li>     <li>NADL and SDRL originally agreed in January to a  $25M funding arrangement maturing March 31, and have since increased the available funding twice, to $50M on April 25 and again to $150M <a href=\"https://seekingalpha.com/news/3276170-seadrill-pumps-another-100m-north-atlantic-drilling\" target=\"_blank\">last month</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283417\" data-linked=\"Seadrill extends North Atlantic Drilling loan maturity date\" data-tweet=\"$NADL $NADL $SDRL - Seadrill extends North Atlantic Drilling loan maturity date https://seekingalpha.com/news/3283417-seadrill-extends-north-atlantic-drilling-loan-maturity-date?source=tweet\" data-url=\"https://seekingalpha.com/news/3283417-seadrill-extends-north-atlantic-drilling-loan-maturity-date\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283414\" data-ts=\"1501524564\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCOI\" target=\"_blank\">CCOI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283414-cogent-communicationsminus-4_1-off-wall-street-starts-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cogent Communications -4.1% as Off Wall Street starts at Sell</a></h4><ul>   <li>Cogent Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/CCOI' title='Cogent Communications Group, Inc.'>CCOI</a>) is <font color='red'>off 4.1%</font> after an initiation at Sell by Off Wall Street.</li>    <li>The firm says Cogent's unlikely to hit revenue growth expectations. The company <a href=\"https://seekingalpha.com/news/3263418-cogent-communications-eps-line-misses-revenue\" target=\"_blank\">missed revenue expectations</a> in May after growing them 8.2% Y/Y, and in its call forecast full-year growth (ex-forex) of 10-20%.</li>    <li>Off Wall Street has set a price target of $29, implying 31.6% downside from today's lower price.</li>    <li>Cogent is set to report before the opening bell on Thursday.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283414\" data-linked=\"Cogent Communications -4.1% as Off Wall Street starts at Sell\" data-tweet=\"$CCOI - Cogent Communications -4.1% as Off Wall Street starts at Sell https://seekingalpha.com/news/3283414-cogent-communicationsminus-4_1-off-wall-street-starts-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3283414-cogent-communicationsminus-4_1-off-wall-street-starts-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283410\" data-ts=\"1501524098\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDHL\" target=\"_blank\">RDHL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283410-redhills-late-stage-study-of-rhbminus-104-in-crohns-to-continue-planned-enrollment-to-be\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RedHill&#39;s late-stage study of RHB-104 in Crohn&#39;s to continue as planned, enrollment to be completed in H1 2018; shares ease 2% on extended completion date</a></h4><ul><li>The independent Data and Safety Monitoring Board &#40;DSMD&#41; has <a href=\"https://seekingalpha.com/pr/16900779-redhill-biopharma-announces-unanimous-positive-dsmb-recommendation-continuation-phase-iii\" target=\"_blank\">recommended </a>that RedHill Biopharma's (<a href='https://seekingalpha.com/symbol/RDHL' title='RedHill Biopharma Ltd.'>RDHL</a> <font color='red'>-2.1%</font>) Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT01951326?term=rhb-104&amp;cond=Crohn+Disease&amp;spons=redhill&amp;rank=1\" target=\"_blank\">MAP US</a>, assessing RHB-104 for the treatment of Crohn's disease continue as planned.</li><li>So far, over 300 of the projected 410 subjects have been randomized. A third DSMB meeting will take place after 75% of the 410 participants have completed 26 weeks on study. Enrollment should be completed in H1 2018 which will extend the estimated primary completion date out until mid-year 2018 or longer.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3278151-redhill-updates-crohns-candidate-rhbminus-104-second-dsmb-review-later-month\" target=\"_blank\">RedHill updates on Crohn's candidate RHB-104, second DSMB review later this month</a> (July 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3283410\" data-linked=\"RedHill&#39;s late-stage study of RHB-104 in Crohn&#39;s to continue as planned, enrollment to be completed in H1 2018; shares ease 2% on extended completion date\" data-tweet=\"$RDHL - RedHill&#39;s late-stage study of RHB-104 in Crohn&#39;s to continue as planned, enrollment to be completed in H1 2018; shares ease 2% on extended completion date https://seekingalpha.com/news/3283410-redhills-late-stage-study-of-rhbminus-104-in-crohns-to-continue-planned-enrollment-to-be?source=tweet\" data-url=\"https://seekingalpha.com/news/3283410-redhills-late-stage-study-of-rhbminus-104-in-crohns-to-continue-planned-enrollment-to-be\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283412\" data-ts=\"1501524063\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283412-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AHGP' title='Alliance Holdings GP, L.P.'>AHGP</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/ACET' title='Aceto Corporation'>ACET</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/WMLP-OLD' title='Westmoreland Resource Partners, LP'>WMLP-OLD</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs, Inc.'>CLF</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/HOS' title='Hornbeck Offshore Services, Inc.'>HOS</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/OIS' title='Oil States International Inc.'>OIS</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/LXU' title='LSB Industries, Inc.'>LXU</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3283412\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$AHGP $YTEN $ACET - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3283412-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3283412-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283400\" data-ts=\"1501520465\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICPT\" target=\"_blank\">ICPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283400-intercepts-q2-beat-cant-overcome-pressure-from-reported-death-in-mid-stage-nash-study-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intercept&#39;s Q2 beat can&#39;t overcome pressure from reported death in mid-stage NASH study; shares down 8%</a></h4><ul><li>Intercept Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a> <font color='red'>-8.1%</font>) slumps on almost 4x higher volume after the company reported a patient death in its Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02633956?titles=control&amp;spons=intercept+pharmaceuticals&amp;rank=1\" target=\"_blank\">CONTROL</a>, assessing obeticholic acid &#40;OCA&#41;&nbsp;in NASH patients. The company <a href=\"https://seekingalpha.com/article/4092741-intercept-pharmaceuticals-icpt-q2-2017-results-earnings-call-transcript?page=6\" target=\"_blank\">says </a>it cannot rule out the possibility that was related to OCA despite the poor health of the patient and the determination by the investigator and Data and Safety Monitoring Committee &#40;DSMC&#41; that it was not.</li><li>OCA, branded as Ocaliva, is approved in the EU and Canada to treat a chronic liver disease called primary biliary cholangitis, also know as primary biliary cirrhosis. NASH, though, is the largest market opportunity.</li></ul><div class=\"tiny-share-widget\" data-id=\"3283400\" data-linked=\"Intercept&#39;s Q2 beat can&#39;t overcome pressure from reported death in mid-stage NASH study; shares down 8%\" data-tweet=\"$ICPT - Intercept&#39;s Q2 beat can&#39;t overcome pressure from reported death in mid-stage NASH study; shares down 8% https://seekingalpha.com/news/3283400-intercepts-q2-beat-cant-overcome-pressure-from-reported-death-in-mid-stage-nash-study-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3283400-intercepts-q2-beat-cant-overcome-pressure-from-reported-death-in-mid-stage-nash-study-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283399\" data-ts=\"1501520431\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283399-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/CNA' title='CNA Financial Corporation'>CNA</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/SAR' title='Saratoga Investment Corp'>SAR</a> <font color='green'>+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3283399\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$YRD $CNA $SAR - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3283399-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3283399-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283398\" data-ts=\"1501519635\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283398-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a> <font color='green'>+75%</font>. <a href='https://seekingalpha.com/symbol/CDI' title='CDI Corporation'>CDI</a> <font color='green'>+32%</font>. <a href='https://seekingalpha.com/symbol/NOVN' title='Novan'>NOVN</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/SBBP' title='Strongbridge Biopharma'>SBBP</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/MYO' title='Myomo, Inc.'>MYO</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/SOHU' title='Sohu.com Inc.'>SOHU</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/AHGP' title='Alliance Holdings GP, L.P.'>AHGP</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/AIRI' title='Air Industries Group, Inc.'>AIRI</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SERV' title='ServiceMaster Global'>SERV</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/DTEA' title='DAVIDs TEA'>DTEA</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NVIV' title='InVivo Therapeutics Holdings Corp'>NVIV</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/ELSE' title='Electro-Sensors, Inc.'>ELSE</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/HTZ' title='Hertz Global Holdings, Inc.'>HTZ</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/NCI' title='Navigant Consulting, Inc.'>NCI</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/OMNT' title='Ominto, Inc.'>OTCPK:OMNT</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/HLTH' title='Nobilis Health Corp.'>HLTH</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/PLSE' title='Pulse Biosciences'>PLSE</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283398\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$DVAX $CDI $NOVN - Midday Gainers / Losers https://seekingalpha.com/news/3283398-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3283398-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283397\" data-ts=\"1501519303\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SERV\" target=\"_blank\">SERV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283397-servicemaster-global-rallies-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ServiceMaster Global rallies after earnings</a></h4><ul> <li>ServiceMaster Global (<a href='https://seekingalpha.com/symbol/SERV' title='ServiceMaster Global'>SERV</a> <font color='green'>+7.2%</font>) jumps after setting full year revenue guidance just above the consensus estimates.</li> <li>The company expects FY revenue of $2.90B to $2.92B vs. $2.90B consensus. EBITDA of $675M is anticipated for the full year vs. $691M consensus.</li> <li>Adjusted EBITDA was up 3% Y/Y to $210M during <a href=\"https://seekingalpha.com/pr/16900639-servicemaster-global-holdings-inc-reports-second-quarter-2017-financial-results\" target=\"_blank\">Q2</a>. 3% organic growth was realized for the Terminix business, although the company cited continued margin pressure as investments in its sales and service delivery were made.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3283234-servicemaster-global-eps-line-beats-revenue\" target=\"_blank\">ServiceMaster Global EPS in-line, beats on revenue</a> (July 31)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283397\" data-linked=\"ServiceMaster Global rallies after earnings\" data-tweet=\"$SERV - ServiceMaster Global rallies after earnings https://seekingalpha.com/news/3283397-servicemaster-global-rallies-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3283397-servicemaster-global-rallies-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283395\" data-ts=\"1501519036\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BRKR\" target=\"_blank\">BRKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283395-fda-clears-expanded-claim-for-brukers-microbial-id-system-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA clears expanded claim for Bruker&#39;s microbial ID system; shares up 1%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16900613-bruker-announces-us-fda-clearance-expanded-3rd-claim-maldi-biotyper\" target=\"_blank\">grants </a>510(k) clearance for a third expanded claim for Bruker's (<a href='https://seekingalpha.com/symbol/BRKR' title='Bruker Corporation'>BRKR</a> <font color='green'>+1%</font>) benchtop MALDI Biotyper-CA. The approval expands the system's microbial reference library by 144 new species, including anaerobes, Gram-positive and Gram-negative bacteria and yeasts. The library now covers 424 microbial species in 333 different groups.</li><li>The MALDI Biotyper is used in clinical microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product safety and quality control and marine microbiology.</li></ul><div class=\"tiny-share-widget\" data-id=\"3283395\" data-linked=\"FDA clears expanded claim for Bruker&#39;s microbial ID system; shares up 1%\" data-tweet=\"$BRKR - FDA clears expanded claim for Bruker&#39;s microbial ID system; shares up 1% https://seekingalpha.com/news/3283395-fda-clears-expanded-claim-for-brukers-microbial-id-system-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3283395-fda-clears-expanded-claim-for-brukers-microbial-id-system-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283394\" data-ts=\"1501519002\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYOU\" target=\"_blank\">CYOU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283394-changyou-comminus-1_7-amid-q2-beat-dim-q3-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Changyou.com -1.7% amid Q2 beat, dim Q3 guidance</a></h4><ul>   <li>Changyou.com (<a href=\"http://seekingalpha.com/symbol/CYOU\" target=\"_blank\">CYOU</a> <font color='red'>-1.7%</font>) posted <a href=\"https://seekingalpha.com/news/3283171-changyou-com-beats-0_32-beats-revenue\" target=\"_blank\">Q2 profits</a> that topped even the highest estimate, but offered guidance below expectations for Q3.</li>    <li>It also noted Chief Financial Officer Jasmine Zhou is resigning for personal reasons. She's agreed to a board request to stay on to allow time for finding a replacement.</li>    <li>Average monthly active accounts for PC games were 2.4M (down 17% Y/Y), and for mobile games 7.4M (up 208% Y/Y).</li>    <li>Quarterly aggregate active paying accounts for PC games were down 10% to 0.9M; for mobile games, up 317% to 2.5M.</li>    <li>Revenue by segment: Online game, $122.4M (up 23.4%); Online advertising, $7.1M (down 38.9%); Cinema advertising, $17.4M (up 28.1%); Internet value-added services, $3.5M (down 27.2%).</li>    <li>For Q3, it's guiding to revenue of $160M-$170M (of that, online game revenue of $120M-$130M), light of an expected $190.8M. It sees non-GAAP income per ADS at $1.02-$1.12, below expectations for $1.21.</li>    <li><a href=\"https://seekingalpha.com/pr/16900488-changyou-reports-second-quarter-2017-unaudited-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3283394\" data-linked=\"Changyou.com -1.7% amid Q2 beat, dim Q3 guidance\" data-tweet=\"$CYOU - Changyou.com -1.7% amid Q2 beat, dim Q3 guidance https://seekingalpha.com/news/3283394-changyou-comminus-1_7-amid-q2-beat-dim-q3-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3283394-changyou-comminus-1_7-amid-q2-beat-dim-q3-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283387\" data-ts=\"1501517710\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAH\" target=\"_blank\">CAH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283387-cardinal-health-completes-acquisition-of-medtronics-patient-recovery-business-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cardinal Health completes acquisition of Medtronic&#39;s patient recovery business; shares up 1%</a></h4><ul><li>Cardinal Health (<a href='https://seekingalpha.com/symbol/CAH' title='Cardinal Health Inc.'>CAH</a> <font color='green'>+1.1%</font>) <a href=\"https://seekingalpha.com/pr/16900461-cardinal-health-completes-acquisition-medtronics-patient-recovery-business\" target=\"_blank\">finalizes </a>its $6.1B deal with Medtronic acquiring three of its businesses: Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency.</li><li>The company says the deal should be accretive to non-GAAP EPS by more than $0.21 in fiscal 2018, net of incremental interest expense related to financing, expanding to more than $0.55 in fiscal 2019.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3257503-cardinal-health-buys-three-businesses-medtronic-6_1b-shares-7-percent-premarket\" target=\"_blank\">Cardinal Health buys three businesses from Medtronic for $6.1B; shares down 7% premarket</a> (April 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3283387\" data-linked=\"Cardinal Health completes acquisition of Medtronic&#39;s patient recovery business; shares up 1%\" data-tweet=\"$CAH - Cardinal Health completes acquisition of Medtronic&#39;s patient recovery business; shares up 1% https://seekingalpha.com/news/3283387-cardinal-health-completes-acquisition-of-medtronics-patient-recovery-business-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3283387-cardinal-health-completes-acquisition-of-medtronics-patient-recovery-business-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283386\" data-ts=\"1501517428\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TDW\" target=\"_blank\">TDW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283386-tidewater-emerges-from-chapter-11-after-completing-restructuring\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tidewater emerges from Chapter 11 after completing restructuring</a></h4><ul>     <li>Tidewater (<a href='https://seekingalpha.com/symbol/TDW' title='Tidewater, Inc.'>TDW</a> <font color='green'>+3.8%</font>) says it has <a href=\"https://seekingalpha.com/pr/16901237-tidewater-successfully-completes-financial-restructuring-emerges-chapter-11-bankruptcy\" target=\"_blank\">emerged from Chapter 11 bankruptcy</a> after successfully completing its reorganization plan.</li>     <li>TDW says the plan eliminated $1.6B in principal of outstanding debt and estimates interest and operating lease expenses will be reduced by ~$73M/year.</li>     <li>TDW says its shares have been approved for listing on the NYSE under its same ticker symbol.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283386\" data-linked=\"Tidewater emerges from Chapter 11 after completing restructuring\" data-tweet=\"$TDW - Tidewater emerges from Chapter 11 after completing restructuring https://seekingalpha.com/news/3283386-tidewater-emerges-from-chapter-11-after-completing-restructuring?source=tweet\" data-url=\"https://seekingalpha.com/news/3283386-tidewater-emerges-from-chapter-11-after-completing-restructuring\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283382\" data-ts=\"1501516958\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283382-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/CELH' title='Celsius Holdings, Inc.'>CELH</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3283382\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$KBSF $CELH $ADOM - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3283382-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3283382-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283374\" data-ts=\"1501516189\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVIV\" target=\"_blank\">NVIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283374-invivo-stops-enrollment-in-inspire-study-after-third-death-shares-down-24\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">InVivo stops enrollment in INSPIRE study after third death; shares down 24%</a></h4><ul><li>Thinly traded nano cap InVivo Therapeutics (<a href='https://seekingalpha.com/symbol/NVIV' title='InVivo Therapeutics Holdings Corp'>NVIV</a> <font color='red'>-23.5%</font>) slumps on a 4x surge in volume after it <a href=\"https://seekingalpha.com/pr/16900747-invivo-therapeutics-announces-updates-inspire-study\" target=\"_blank\">announced </a>a temporary suspension of enrollment in its Phase 3 INSPIRE study assessing its Neuro-Spinal Scaffold in patients with complete thoracic spinal cord injury.</li><li>The company took action after a third study participant died, although determined by the principal investigator to be unrelated to the product. It plans to discuss the situation with the FDA to ascertain whether modifications to the study are necessary or any changes to patient enrollment criteria.</li><li>The completion of enrollment is now projected to occur in H1 2018 with a Humanitarian Device Exemption &#40;HDE&#41; application to follow in H2 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3283374\" data-linked=\"InVivo stops enrollment in INSPIRE study after third death; shares down 24%\" data-tweet=\"$NVIV - InVivo stops enrollment in INSPIRE study after third death; shares down 24% https://seekingalpha.com/news/3283374-invivo-stops-enrollment-in-inspire-study-after-third-death-shares-down-24?source=tweet\" data-url=\"https://seekingalpha.com/news/3283374-invivo-stops-enrollment-in-inspire-study-after-third-death-shares-down-24\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283372\" data-ts=\"1501514851\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283372-facebookminus-1_7-pivotal-cuts-to-sell-sees-17_5-downside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Facebook -1.7% as Pivotal cuts to Sell, sees 17.5% downside</a></h4><ul>   <li>Facebook (<a href=\"http://seekingalpha.com/symbol/FB\" target=\"_blank\">FB</a> <font color='red'>-1.7%</font>) is lower today amid a downgrade to Sell at Pivotal Research, which sees the rest of the Street underestimating risks including harbingers of ad spending slowdowns.</li>    <li>The stock is \"simply too expensive,\" writes analyst Brian Wieser, who maintains a $140 price target, 17.5% lower than today's price.</li>    <li>Wieser points to a digital ad market nearing saturation, with a nod to top advertiser <a href=\"https://twitter.com/ReformedBroker/status/892041528683712512\" target=\"_blank\">Procter &amp; Gamble and its cutbacks</a> tied to inappropriate placements. The fact that P&amp;G said $140M in reductions didn't impact revenue growth suggests large brands (from which he estimates Facebook gets 30% of revenues) may be more discerning on digital ad spending.</li>    <li>Pivotal also says Europe's hard line on dominant companies like Facebook hints at more regulatory risk ahead, notably consumer privacy rules that take effect next spring.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283372\" data-linked=\"Facebook -1.7% as Pivotal cuts to Sell, sees 17.5% downside\" data-tweet=\"$FB - Facebook -1.7% as Pivotal cuts to Sell, sees 17.5% downside https://seekingalpha.com/news/3283372-facebookminus-1_7-pivotal-cuts-to-sell-sees-17_5-downside?source=tweet\" data-url=\"https://seekingalpha.com/news/3283372-facebookminus-1_7-pivotal-cuts-to-sell-sees-17_5-downside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>78&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283368\" data-ts=\"1501514088\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARAY\" target=\"_blank\">ARAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283368-fda-clears-accurays-data-management-upgrade-for-tomotherapy-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA clears Accuray&#39;s data management upgrade for TomoTherapy; shares up 1%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16900677-accuray-receives-510-k-clearance-idms-data-management-system-upgrade-tomotherapy-system\" target=\"_blank\">grants </a>510(k) clearance for Accuray's (<a href='https://seekingalpha.com/symbol/ARAY' title='Accuray Incorporated'>ARAY</a> <font color='green'>+1.2%</font>) iDMS Data Management System for use with its TomoTherapy platform. The company says iDMS, a centralized database, is compatible with multiple technologies including Radixact, CyberKnife and the Accuray Precision Treatment Planning System, in addition to TomoTherapy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3283368\" data-linked=\"FDA clears Accuray&#39;s data management upgrade for TomoTherapy; shares up 1%\" data-tweet=\"$ARAY - FDA clears Accuray&#39;s data management upgrade for TomoTherapy; shares up 1% https://seekingalpha.com/news/3283368-fda-clears-accurays-data-management-upgrade-for-tomotherapy-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3283368-fda-clears-accurays-data-management-upgrade-for-tomotherapy-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283366\" data-ts=\"1501513990\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCOM\" target=\"_blank\">BCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283366-b-communicationsplus-6_9-elovitch-looks-to-pay-debts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">B Communications +6.9% as Elovitch looks to pay debts</a></h4><ul>   <li>B Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/BCOM' title='B Communications Ltd.'>BCOM</a>), the Nasdaq-traded owner of Israel's Bezeq (<a href=\"http://seekingalpha.com/symbol/BZQIY\" target=\"_blank\">BZQIY</a> <font color='green'>+2.3%</font>), is <font color='green'>up 6.9%</font> in U.S. trading, recovering some of a July decline.</li>    <li>The company's controlling shareholder, Shaul Elovitch, is reportedly <a href=\"http://www.timesofisrael.com/bezeq-owner-reportedly-offers-to-sell-stakes-to-pay-off-debt/\" target=\"_blank\">offering to sell stakes</a> in a 1B-shekel bid (about $281M) to pay off debt.</li>    <li>That's how much Elovitch owes to banks. He's proposing selling 600M shekels worth of assets in the coming year, and later selling 15% of Bezeq shares at 5% a year.</li>    <li>Elovitch's Eurocom Communications controls Internet Gold-Golden Lines, which controls B Communications.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283366\" data-linked=\"B Communications +6.9% as Elovitch looks to pay debts\" data-tweet=\"$BCOM $BCOM $BZQIY - B Communications +6.9% as Elovitch looks to pay debts https://seekingalpha.com/news/3283366-b-communicationsplus-6_9-elovitch-looks-to-pay-debts?source=tweet\" data-url=\"https://seekingalpha.com/news/3283366-b-communicationsplus-6_9-elovitch-looks-to-pay-debts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283336\" data-ts=\"1501513252\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283336-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a> <font color='green'>+68%</font>. <a href='https://seekingalpha.com/symbol/NOVN' title='Novan'>NOVN</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/MYO' title='Myomo, Inc.'>MYO</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/APEN' title='Apollo Endosurgery'>APEN</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/HSKA' title='Heska Corporation'>HSKA</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NVIV' title='InVivo Therapeutics Holdings Corp'>NVIV</a> <font color='red'>-28%</font>. <a href='https://seekingalpha.com/symbol/ABIO' title='ARCA biopharma, Inc.'>ABIO</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/IMDZ' title='Immune Design'>IMDZ</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3283336\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$DVAX $NOVN $MYO - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3283336-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3283336-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283362\" data-ts=\"1501512861\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NWE\" target=\"_blank\">NWE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283362-nothwestern-cut-to-sell-williams-capital-on-montana-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NothWestern cut to Sell at Williams Capital on Montana concerns</a></h4><ul>     <li>NorthWestern (<a href='https://seekingalpha.com/symbol/NWE' title='NorthWestern Corporation'>NWE</a> <font color='red'>-1.9%</font>) is <a href=\"https://www.streetinsider.com/Downgrades/Williams+Capital+Downgrades+Northwestern+Corp.+%28NWE%29+to+Sell/13146763.html\" target=\"_blank\">downgraded to Sell</a> from Hold with a $52 price target, cut from $64, at Williams Capital, which urges investor caution on developments in Montana.</li><li>Williams notes that the Montana Public Service Commission held additional testimony in docket on Friday morning to review NWE's supply tracker, and is concerned based on the meeting that the PSC intends a material reduction in the company's revenues relatively soon.</li><li>The firm says it cannot be certain how or when but that it would bet the PSC is trying hard to  beat the company to a GRC filing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3283362\" data-linked=\"NothWestern cut to Sell at Williams Capital on Montana concerns\" data-tweet=\"$NWE - NothWestern cut to Sell at Williams Capital on Montana concerns https://seekingalpha.com/news/3283362-nothwestern-cut-to-sell-williams-capital-on-montana-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/3283362-nothwestern-cut-to-sell-williams-capital-on-montana-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283361\" data-ts=\"1501512641\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANFI\" target=\"_blank\">ANFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283361-amira-nature-foods-rallies-trends-improve\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amira Nature Foods rallies as trends improve</a></h4><ul> <li>Amira Nature Foods (<a href='https://seekingalpha.com/symbol/ANFI' title='Amira Nature Foods'>ANFI</a> <font color='green'>+4.1%</font>) trades higher after posting <a href=\"https://seekingalpha.com/pr/16900675-amira-nature-foods-ltd-announces-financials-results-six-months-fiscal-year-ended-march-31\" target=\"_blank\">results</a> for the second half of its fiscal year.</li> <li>The company reported an EBITDA margin of 12.6% on revenue of $341M.</li> <li>\"Our growth accelerated as we progressed through the year and we have passed an inflection point in the business where our rate of growth increased from down in the first half of the fiscal year to up 3% year-over-year through the six months ended March 31,\" notes CFO Bruce Wacha.</li> <li>Pricing actions are expected to benefit Amira moving forward.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3283254-amira-nature-foods-reports-2h-results\" target=\"_blank\">Amira Nature Foods reports 2H results</a> (July 31)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283361\" data-linked=\"Amira Nature Foods rallies as trends improve\" data-tweet=\"$ANFI - Amira Nature Foods rallies as trends improve https://seekingalpha.com/news/3283361-amira-nature-foods-rallies-trends-improve?source=tweet\" data-url=\"https://seekingalpha.com/news/3283361-amira-nature-foods-rallies-trends-improve\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283358\" data-ts=\"1501512086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283358-astrazenecas-imfinzi-breakthrough-therapy-for-certain-lung-cancer-shares-ahead-7-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca&#39;s Imfinzi a Breakthrough Therapy for certain lung cancer; shares ahead 7% as shares rebound after recent Phase 3 flop</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16900615-imfinzi-durvalumab-granted-breakthrough-therapy-designation-us-fda-patients-locally-advanced\" target=\"_blank\">designates </a>AstraZeneca's (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color='green'>+6.5%</font>) IMFINZI (durvalumab) a Breakthrough Therapy for the treatment of locally advanced, unresectable non-small lung cancer &#40;NSCLC&#41; that has not progressed after platinum-based chemo, the second such designation for the PD-L1 inhibitor (it received accelerated approval in May in the U.S. for urothelial carcinoma).</li><li>Breakthrough Therapy status provides for more intensive guidance from the FDA, the involvement of more senior agency personnel and a rolling review of the marketing application.</li><li>Shares have rebounded over&nbsp;<font color='green'>8%</font>&nbsp;since bottoming at $28.43 last Thursday. Shares plummeted after the company announced failed results from the Phase 3 MYSTIC study.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3282146-astrazeneca-15-percent-premarket-failed-late-stage-study-lung-cancer-candidate-durvalumab\" target=\"_blank\">AstraZeneca down 15% premarket on failed late-stage study on lung cancer candidate durvalumab; Merck up 5% on improved prospects for Keytruda</a> (July 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3283358\" data-linked=\"AstraZeneca&#39;s Imfinzi a Breakthrough Therapy for certain lung cancer; shares ahead 7% as shares rebound after recent Phase 3 flop\" data-tweet=\"$AZN - AstraZeneca&#39;s Imfinzi a Breakthrough Therapy for certain lung cancer; shares ahead 7% as shares rebound after recent Phase 3 flop https://seekingalpha.com/news/3283358-astrazenecas-imfinzi-breakthrough-therapy-for-certain-lung-cancer-shares-ahead-7-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3283358-astrazenecas-imfinzi-breakthrough-therapy-for-certain-lung-cancer-shares-ahead-7-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283350\" data-ts=\"1501511002\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHTR\" target=\"_blank\">CHTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283350-cable-firms-rise-sprint-merger-saga-develops\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cable firms rise as Sprint merger saga develops</a></h4><ul>   <li>After a firm statement that it's <a href=\"https://seekingalpha.com/news/3283169-wsj-charter-sprint-deal\" target=\"_blank\">not interested in a merger</a> with Sprint (<a href=\"http://seekingalpha.com/symbol/S\" target=\"_blank\">S</a> <font color='red'>-1.5%</font>), Charter Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/CHTR' title='Charter Communications, Inc.'>CHTR</a>) is <font color='green'>up 4.7%</font> and tapped a new all-time high at the open this morning.</li>    <li>Charter added in its statement that its MVNO relationship with Verizon (<a href=\"http://seekingalpha.com/symbol/VZ\" target=\"_blank\">VZ</a> <font color='green'>+0.1%</font>) is \"very good.\"</li>    <li>Charter rival Comcast (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) is up too, <font color='green'>+2.1%</font>, and Altice USA (NYSE:<a href='https://seekingalpha.com/symbol/ATUS' title='Altice USA'>ATUS</a>) <font color='green'>up 3.9%</font>, after late word that Sprint parent SoftBank (<a href='https://seekingalpha.com/symbol/SFTBY' title='SoftBank Group ADR'>OTCPK:SFTBY</a>) wants to make a <a href=\"https://seekingalpha.com/news/3283192-softbank-closes-charter\" target=\"_blank\">direct bid</a> for Charter.</li>    <li>Also up are cable titan John Malone's properties: <a href='https://seekingalpha.com/symbol/LBRDA' title='Liberty Broadband Corporation'>LBRDA</a> <font color='green'>+4.8%</font>; LVNTA <font color='green'>+4.6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283350\" data-linked=\"Cable firms rise as Sprint merger saga develops\" data-tweet=\"$CHTR $CHTR $CMCSA - Cable firms rise as Sprint merger saga develops https://seekingalpha.com/news/3283350-cable-firms-rise-sprint-merger-saga-develops?source=tweet\" data-url=\"https://seekingalpha.com/news/3283350-cable-firms-rise-sprint-merger-saga-develops\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>68&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283347\" data-ts=\"1501510156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPCI\" target=\"_blank\">IPCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283347-intellipharmaceutics-to-vigorously-defend-in-class-action-suit-shares-down-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intellipharmaceutics to &quot;vigorously&quot; defend itself in class action suit; shares down 6%</a></h4><ul><li>In a statement, Intellipharmaceutics (<a href='https://seekingalpha.com/symbol/IPCI' title='IntelliPharmaCeutics International Inc'>IPCI</a> <font color='red'>-6%</font>) says it will \"vigorously\" defend itself in a <a href=\"https://seekingalpha.com/pr/16900766-intellipharmaceutics-intends-vigorously-defend-recently-filed-purported-class-action-lawsuit\" target=\"_blank\">class action lawsuit</a> filed on Friday, July 28, in a New York district court that accuses the company and certain executives of allegedly making false and misleading statements regarding its U.S. marketing application for abuse-deterrent opioid Rexista (oxycodone) extended-release tablets.</li><li>Shares plummeted last Wednesday after an FDA advisory committee rejected its marketing application.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3281760-fda-ad-com-thumbs-intellipharmaceutics-oxycodone\" target=\"_blank\">FDA Ad Com thumbs down on Intellipharmaceutics' oxycodone</a> (July 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3283347\" data-linked=\"Intellipharmaceutics to &quot;vigorously&quot; defend itself in class action suit; shares down 6%\" data-tweet=\"$IPCI - Intellipharmaceutics to &quot;vigorously&quot; defend itself in class action suit; shares down 6% https://seekingalpha.com/news/3283347-intellipharmaceutics-to-vigorously-defend-in-class-action-suit-shares-down-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3283347-intellipharmaceutics-to-vigorously-defend-in-class-action-suit-shares-down-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283339\" data-ts=\"1501509535\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMP\" target=\"_blank\">SMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283339-on-standard-motor-products-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Standard Motor Products&#39; Q2</a></h4><ul>     <li>Standard Motor Products (<a href='https://seekingalpha.com/symbol/SMP' title='Standard Motor Products, Inc.'>SMP</a> <font color='red'>-7.4%</font>)&nbsp;reports&nbsp;Engine management revenue rose 12.3% to $223.35M in <a href=\"https://seekingalpha.com/pr/16900857-standard-motor-products-inc-announces-second-quarter-2017-results-quarterly-dividend\" target=\"_blank\">Q2</a>.</li>     <li>Goss margin rate declined 110 bps to 29%.</li>     <li>SG&amp;A expense rate +30 bps to 19.2%.</li>     <li>Operating margin rate slipped 150 bps to 9.5%.</li>     <li>Mr.&nbsp;Eric P. Sills, Standard Motor Products' Chief Executive Officer and President stated, \"A key factor in the second quarter was the step back in Engine Management gross margin, from 32.1% in 2016 to 29.4% this year. This led to a decline in earnings in the second quarter, though we remain ahead of 2016 in both sales and earnings year-to-date. This gross margin decline is primarily the result of the previously announced plant moves. These are proceeding according to plan, and we are pleased with the progress.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283339\" data-linked=\"More on Standard Motor Products&#39; Q2\" data-tweet=\"$SMP - More on Standard Motor Products&#39; Q2 https://seekingalpha.com/news/3283339-on-standard-motor-products-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3283339-on-standard-motor-products-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283338\" data-ts=\"1501509421\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBER\" target=\"_blank\">UBER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283338-cnbc-softbanks-uber-investment-talks-dead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CNBC: SoftBank&#39;s Uber investment talks &#39;dead&#39;</a></h4><ul>   <li>SoftBank (<a href=\"http://seekingalpha.com/symbol/SFTBY\" target=\"_blank\">SFTBY</a> <font color='red'>-2.3%</font>) plans to <a href=\"https://seekingalpha.com/news/3280627-report-softbanks-son-mulls-massive-stake-uber\" target=\"_blank\">take a possibly \"massive\" stake</a> in Uber (<a href='https://seekingalpha.com/symbol/UBER' title='Uber'>UBER</a>) <a href=\"https://www.cnbc.com/2017/07/31/softbank-talks-to-invest-in-uber-are-dead-sources-tell-cnbc.html\" target=\"_blank\">are dead</a>, CNBC reports.</li>    <li>Talks that the Japanese conglomerate held with Uber shareholders including Benchmark now appear to be off, David Faber says he's hearing from sources.</li>    <li>SoftBank has existing positions in Uber's international rivals Ola and Didi Chuxing, and along with Didi it has a $2B stake in Singapore's Grab.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283338\" data-linked=\"CNBC: SoftBank&#39;s Uber investment talks &#39;dead&#39;\" data-tweet=\"$UBER $UBER $SFTBY - CNBC: SoftBank&#39;s Uber investment talks &#39;dead&#39; https://seekingalpha.com/news/3283338-cnbc-softbanks-uber-investment-talks-dead?source=tweet\" data-url=\"https://seekingalpha.com/news/3283338-cnbc-softbanks-uber-investment-talks-dead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283337\" data-ts=\"1501509399\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDS\" target=\"_blank\">DDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283337-activist-action-lifts-dillards\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Activist action lifts Dillard&#39;s</a></h4><ul> <li>Dillard's (<a href='https://seekingalpha.com/symbol/DDS' title='Dillard&#39;s Inc.'>DDS</a> <font color='green'>+4.8%</font>) moves higher after the company becomes the target of activist investor Snow Park Capital Parners.</li> <li>Snow Park thinks Dillard's is worth more than $200 per share on the value of its real estate. \"Dillard's is essentially an underleveraged real estate company that is masquerading as a low productivity retailer,\" according to Snow Park Managing Partner Jeff Pierce.</li> <li>Bloomberg reports that Snow Park holds about a 2% stake in Dillard's Class A stock.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283337\" data-linked=\"Activist action lifts Dillard&#39;s\" data-tweet=\"$DDS - Activist action lifts Dillard&#39;s https://seekingalpha.com/news/3283337-activist-action-lifts-dillards?source=tweet\" data-url=\"https://seekingalpha.com/news/3283337-activist-action-lifts-dillards\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283334\" data-ts=\"1501509096\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISCA\" target=\"_blank\">DISCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283334-discoveryminus-3_4-after-scripps-networks-deal-news-earnings-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Discovery -3.4% after Scripps Networks deal news, earnings miss</a></h4><ul>   <li>Discovery Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/DISCA' title='Discovery Inc A'>DISCA</a>) is <font color='red'>3.4% lower</font> in early trading today after news that it will <a href=\"https://seekingalpha.com/news/3283231-discovery-communications-acquires-scripps-networks-interactive\" target=\"_blank\">acquire Scripps Networks Interactive</a> (NYSE:<a href='https://seekingalpha.com/symbol/SNI' title='Scripps Networks Interactive, Inc.'>SNI</a>) and following a miss on top and bottom lines in its <a href=\"https://seekingalpha.com/news/3283228-discovery-communications-misses-0_04-misses-revenue\" target=\"_blank\">Q2 earnings</a>.</li>       <li>A heavy international focus again bit the company due to foreign exchange effects. Adjusted EPS was down 4% and missed, but was up 9% excluding currency effects.</li>    <li>Distribution revenues made up for relatively flat advertising both in the U.S. and abroad to drive modest revenue gains. Distribution was up 4% in the U.S., and grew 7% (excluding forex) internationally vs. 1% ad growth.</li>    <li>Meanwhile, operating expenses that fell 2% in the U.S. were up 6% (up 8% ex-forex) internationally due to higher sports content and production costs.</li>    <li>Revenue by segment: U.S. Networks, $890M (up 2%); International Networks, $811M (up 3%); Education and other, $44M (down 4%).</li>    <li><a href=\"https://seekingalpha.com/pr/16900597-discovery-communications-reports-second-quarter-2017-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3283334\" data-linked=\"Discovery -3.4% after Scripps Networks deal news, earnings miss\" data-tweet=\"$DISCA $DISCA $SNI - Discovery -3.4% after Scripps Networks deal news, earnings miss https://seekingalpha.com/news/3283334-discoveryminus-3_4-after-scripps-networks-deal-news-earnings-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3283334-discoveryminus-3_4-after-scripps-networks-deal-news-earnings-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283333\" data-ts=\"1501509090\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DAN\" target=\"_blank\">DAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283333-dana-rallies-after-earnings-topper\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dana rallies after earnings topper</a></h4><ul> <li>Dana (<a href='https://seekingalpha.com/symbol/DAN' title='Dana, Inc.'>DAN</a> <font color='green'>+3.9%</font>) trades higher after topping <a href=\"https://seekingalpha.com/pr/16900603-dana-incorporated-announces-second-quarter-2017-financial-results-raises-full-year-guidance\" target=\"_blank\">Q2 estimates</a>.</li> <li>The company brought in adjusted EBITDA of $217M, which represents 11.8% of sales. \"This quarter's strong sales, profit, and cash flow are driven by improved market conditions, our recent acquisitions, and a focus on operational execution,\" notes CEO James Kamsickas.</li> <li>Dana also raises full-year guidance, saying it sees sales growth of 8% and adjusted EBITDA growth of 11% for the period.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3283233-dana-beats-0_17-beats-revenue\" target=\"_blank\">Dana beats by $0.17, beats on revenue</a> (July 31)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283333\" data-linked=\"Dana rallies after earnings topper\" data-tweet=\"$DAN - Dana rallies after earnings topper https://seekingalpha.com/news/3283333-dana-rallies-after-earnings-topper?source=tweet\" data-url=\"https://seekingalpha.com/news/3283333-dana-rallies-after-earnings-topper\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283328\" data-ts=\"1501508367\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTZ\" target=\"_blank\">HTZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283328-hertz-global-down-9-on-barclays-gloom\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hertz Global down 9% on Barclays gloom</a></h4><ul> <li>Hertz Global (NYSE:<a href='https://seekingalpha.com/symbol/HTZ' title='Hertz Global Holdings, Inc.'>HTZ</a>) opens <font color='red'>down 9.08%</font> after Barclays downgrades the car rental stock to Underweight from Equalweight.</li> <li>Analyst Dan Levy warns that investors are underestimating the earnings challenges facing Hertz. He thinks Hertz would have to bring in 2019 EBITDA of $700M to $800M to justify the current share price, much higher than his current estimate of $420M.</li> <li>Barclays sets a price target of $9 on Hertz to represent more than 40% downside potential.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283328\" data-linked=\"Hertz Global down 9% on Barclays gloom\" data-tweet=\"$HTZ - Hertz Global down 9% on Barclays gloom https://seekingalpha.com/news/3283328-hertz-global-down-9-on-barclays-gloom?source=tweet\" data-url=\"https://seekingalpha.com/news/3283328-hertz-global-down-9-on-barclays-gloom\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>48&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283322\" data-ts=\"1501507595\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLIR\" target=\"_blank\">FLIR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283322-flir-systemsminus-4-on-possible-sanctions-violations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FLIR Systems -4% on possible sanctions violations</a></h4><ul>     <li>FLIR&nbsp;Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/FLIR' title='FLIR Systems, Inc.'>FLIR</a>) <font color='red'>-4.2%</font> premarket after disclosing late Friday in its <a href=\"https://www.sec.gov/Archives/edgar/data/354908/000035490817000055/flir-06302017x10q.htm\" target=\"_blank\">Form 10-Q</a> that the Department of Commerce Bureau of Industry and Security informed it of additional export licensing requirements that restrict its ability to sell 9hz thermal products.</li><li>The DoC says some of FLIR's  products may have been sold to countries subject to U.S. sanctions.</li>     <li>FLIR says it could be subject to substantial fines and penalties, suspension of existing licenses and loss or suspension of export privileges if it is found to have violated applicable rules.</li></ul><div class=\"tiny-share-widget\" data-id=\"3283322\" data-linked=\"FLIR Systems -4% on possible sanctions violations\" data-tweet=\"$FLIR - FLIR Systems -4% on possible sanctions violations https://seekingalpha.com/news/3283322-flir-systemsminus-4-on-possible-sanctions-violations?source=tweet\" data-url=\"https://seekingalpha.com/news/3283322-flir-systemsminus-4-on-possible-sanctions-violations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283317\" data-ts=\"1501507047\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283317-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a> <font color='green'>+91%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3283255-premarket-analyst-action-healthcare\" target=\"_blank\">positive</a> rating from JPMorgan.</li>     <li><a href='https://seekingalpha.com/symbol/CDI' title='CDI Corporation'>CDI</a> <font color='green'>+32%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3283304-cdi-acquired-ae-industrial-partners-8_25-per-share-cash\" target=\"_blank\">acquired</a> by AE Industrial Partners.</li>     <li><a href='https://seekingalpha.com/symbol/NXTD' title='NXT-ID Inc.'>NXTD</a> <font color='green'>+23%</font>&nbsp;on H1 prelim <a href=\"https://seekingalpha.com/news/3283310-nxt-id-announces-preliminary-q2-1h-results-shares-ahead-23-percent-premarket\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/MYO' title='Myomo, Inc.'>MYO</a> <font color='green'>+20%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3283305-myomos-powered-arm-brace-ce-markd-shares-ahead-19-percent-premarket\" target=\"_blank\">announcement&nbsp;</a>that its MyoPro myoelectric arm orthosis is now CE Mark certified.</li>     <li><a href='https://seekingalpha.com/symbol/XXII' title='22nd Century Group, Inc.'>XXII</a> <font color='green'>+12%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/SOHU' title='Sohu.com Inc.'>SOHU</a> <font color='green'>+9%</font>&nbsp;on Q2 <a href=\"https://seekingalpha.com/news/3283170-sohu-com-misses-0_27-beats-revenue\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/CHTR' title='Charter Communications, Inc.'>CHTR</a> <font color='green'>+6%</font>&nbsp;as Softbank <a href=\"https://seekingalpha.com/news/3283192-softbank-closes-charter\" target=\"_blank\">closes</a> in on Charter.</li>     <li><a href='https://seekingalpha.com/symbol/NRZ' title='New Residential Investment Corp.'>NRZ</a> <font color='green'>+5%</font>&nbsp;on Q2 <a href=\"https://seekingalpha.com/news/3283230-new-residential-investment-beats-0_50-beats-revenue\" target=\"_blank\">result</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283317\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$DVAX $CDI $NXTD - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3283317-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3283317-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283316\" data-ts=\"1501506697\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283316-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/NVIV' title='InVivo Therapeutics Holdings Corp'>NVIV</a> <font color='red'>-29%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16900747-invivo-therapeutics-announces-updates-inspire-study\" target=\"_blank\">announcing</a> updates on the INSPIRE study.</li><li><a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a>&nbsp;<font color='red'>-7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3283265-bristol-myers-clovis-evaluate-opdivo-rubraca-combo-range-tumors-clovis-6-percent-premarket\" target=\"_blank\">announcing</a> a clinical collaboration with Bristol-Myers to evaluate the combination of Opdivo (nivolumab) and Rubraca (rucaparib) across multiple tumor types.</li><li><a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/HTZ' title='Hertz Global Holdings, Inc.'>HTZ</a> <font color='red'>-7%</font>.</li><li><a href='https://seekingalpha.com/symbol/ROYT' title='Pacific Coast Oil Trust'>ROYT</a> <font color='red'>-6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3283316\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$NVIV $CLVS $DRYS - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3283316-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3283316-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283315\" data-ts=\"1501506549\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REGN\" target=\"_blank\">REGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283315-sanofis-q2-dupixent-sales-of-28_6m-below-expectations-partner-regeneron-down-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sanofi&#39;s Q2 Dupixent sales of $28.6M below expectations; partner Regeneron down 4% premarket</a></h4><ul><li>Regeneron Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a>) slips&nbsp;<font color='red'>4%</font>&nbsp;premarket on modest volume on the heels of commercialization partner Sanofi's (NASDAQ:<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a>) <a href=\"http://mediaroom.sanofi.com/sanofi-raises-fy-2017-business-eps1-guidance-to-broadly-stable-at-cer2/\" target=\"_blank\">Q2 results</a> that included $28.6M in Dupixent (dupilumab) sales, below expectations of $40M - 50M.</li><li>The FDA approved the eczema med in March. It sells for $37K/year. Analysts project peak sales of $5B.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3263633-regeneron-nearly-5-percent-results-dupixent-numbers\" target=\"_blank\">Regeneron up nearly 5% after results, Dupixent numbers</a> (May 4)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253914-fda-oks-regeneron-sanofis-dermatitis-med-dupixent\" target=\"_blank\">FDA OKs Regeneron and Sanofi's dermatitis med Dupixent</a> (March 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3283315\" data-linked=\"Sanofi&#39;s Q2 Dupixent sales of $28.6M below expectations; partner Regeneron down 4% premarket\" data-tweet=\"$REGN $REGN $SNY - Sanofi&#39;s Q2 Dupixent sales of $28.6M below expectations; partner Regeneron down 4% premarket https://seekingalpha.com/news/3283315-sanofis-q2-dupixent-sales-of-28_6m-below-expectations-partner-regeneron-down-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3283315-sanofis-q2-dupixent-sales-of-28_6m-below-expectations-partner-regeneron-down-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283313\" data-ts=\"1501506447\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VALE\" target=\"_blank\">VALE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283313-iron-ore-copper-prices-surge-after-upbeat-china-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iron ore, copper prices surge after upbeat China data</a></h4><ul>     <li><a href=\"https://www.ft.com/content/6e4bb10e-75a0-11e7-a3e8-60495fe6ca71\" target=\"_blank\">Mining stocks are rallying</a> after iron ore prices jumped to their highest level in nearly four months and copper prices reached fresh <a href=\"http://www.marketwatch.com/story/copper-hits-fresh-2-year-high-after-china-data-2017-07-31\" target=\"_blank\">two-year highs</a>, as a gauge of activity in China&rsquo;s construction sector rose to a three and a half year high.</li>     <li>The jump followed news that the official sub-index for activity growth in China&rsquo;s construction sector climbed to 62.5 in July, the highest since December 2013.</li>     <li>Also, an official gauge of manufacturing activity in China came in slightly below expectations - 51.4 vs. an expected 51.6 - but remained in expansion territory.</li>     <li>In U.S. premarket trading: <a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a> <font color='green'>+3.4%</font>, <a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a> <font color='green'>+2.4%</font>, <a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs, Inc.'>CLF</a> <font color='green'>+2.2%</font>, <a href='https://seekingalpha.com/symbol/FCX' title='Freeport-McMoRan Inc.'>FCX</a> <font color='green'>+1.8%</font>, <a href='https://seekingalpha.com/symbol/TECK' title='Teck Resources Limited'>TECK</a> <font color='green'>+1.7%</font>, <a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color='green'>+1.7%</font>, <a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color='green'>+1.3%</font>, <a href='https://seekingalpha.com/symbol/AA' title='Alcoa Corporation'>AA</a> <font color='green'>+1.2%</font>, <a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color='green'>+1.1%</font>.</li><li>Also on watch: <a href='https://seekingalpha.com/symbol/AAUKF' title='Anglo American plc'>OTCQX:AAUKF</a>, <a href='https://seekingalpha.com/symbol/AAUKY' title='Anglo American plc ADR'>OTCPK:AAUKY</a>, <a href='https://seekingalpha.com/symbol/FSUMF' title='Fortescue Metals Group Ltd'>OTCQX:FSUMF</a>, <a href='https://seekingalpha.com/symbol/ANFGF' title='Antofagasta plc'>OTC:ANFGF</a>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/JJC' title='iPath Series B Bloomberg Copper Subindex Total Return ETN'>JJC</a>, <a href='https://seekingalpha.com/symbol/DBB' title='Invesco DB Base Metals ETF'>DBB</a>, <a href='https://seekingalpha.com/symbol/JJN' title='iPath DJ-UBS Nickel Total Return Sub-Index ETN'>JJN</a>, <a href='https://seekingalpha.com/symbol/CPER' title='United States Copper Index ETF'>CPER</a>, <a href='https://seekingalpha.com/symbol/JJU-OLD' title='iPath Dow Jones-UBS Aluminum Total Return Sub-IndexS ETN'>JJU-OLD</a>, <a href='https://seekingalpha.com/symbol/BOM' title='DB Base Metals Double Short ETN'>BOM</a>, <a href='https://seekingalpha.com/symbol/JJT-OLD' title='iPath Dow Jones-UBS Tin Total Return Sub-Index ETN'>JJT-OLD</a>, <a href='https://seekingalpha.com/symbol/BOS' title='DB Base Metals Short ETN'>BOS</a>, <a href='https://seekingalpha.com/symbol/NINI' title='iPath Pure Beta Nickel ETN'>NINI</a>, <a href='https://seekingalpha.com/symbol/LD' title='iPath Dow Jones-UBS Lead Total Return Sub-Index ETN'>LD</a>, <a href='https://seekingalpha.com/symbol/JJM' title='iPath DJ-UBS Industrial Metals Total Return Sub-Index ETN'>JJM</a>, <a href='https://seekingalpha.com/symbol/CUPM' title='iPath Pure Beta Copper ETN'>CUPM</a>, <a href='https://seekingalpha.com/symbol/BDD' title='DB Base Metals Double Long ETN'>BDD</a>, <a href='https://seekingalpha.com/symbol/FOIL' title='iPath Pure Beta Aluminum ETN'>FOIL</a>, <a href='https://seekingalpha.com/symbol/RJZ' title='ELEMENTS Rogers International Commodity Metal ETN'>RJZ</a>, <a href='https://seekingalpha.com/symbol/BDG-OLD' title='DB Base Metals Long ETN'>BDG-OLD</a>, <a href='https://seekingalpha.com/symbol/UBM' title='UBS ETRACS CMCI Industrial Metals Total Return ETN'>UBM</a>, <a href='https://seekingalpha.com/symbol/LEDD' title='iPath Pure Beta Lead ETN'>LEDD</a>, <a href='https://seekingalpha.com/symbol/HEVY' title='iPath Pure Beta Industrial Metals ETN'>HEVY</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3283313\" data-linked=\"Iron ore, copper prices surge after upbeat China data\" data-tweet=\"$VALE $VALE $AKS - Iron ore, copper prices surge after upbeat China data https://seekingalpha.com/news/3283313-iron-ore-copper-prices-surge-after-upbeat-china-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3283313-iron-ore-copper-prices-surge-after-upbeat-china-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283310\" data-ts=\"1501506328\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NXTD\" target=\"_blank\">NXTD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283310-nxt-id-announces-preliminary-q2-and-1h-results-shares-ahead-23-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NXT-ID announces preliminary Q2 and 1H results; shares ahead 23% premarket</a></h4><ul> <li>NXT-ID (NASDAQ:<a href='https://seekingalpha.com/symbol/NXTD' title='NXT-ID Inc.'>NXTD</a>) <a href=\"https://seekingalpha.com/pr/16900784-nxt-id-inc-releases-preliminary-results-six-months-quarter-ended-june-30-2017\" target=\"_blank\">announces</a> selected 1H and Q2 preliminary results for the quarter Ended June 30.</li><li>Revenue was ~$14.3M &nbsp;and&nbsp;~$7.6M&nbsp;for 1H and Q2 respectively.</li><li>Gross profit was ~$7.3M and ~$3.8M for 1H and Q2 respectively.</li><li>Operating expenses were ~$5.5M and ~$3M for 1H and Q2 respectively.</li><li>Operating income for 1H and Q2 was ~$1.8M and ~$0.7 million respectively.</li>   <li>NXT-ID intends to report final Q2 and 1H results on or about August 15, after market close.</li><li>Shares are up&nbsp;<font color='green'>23%</font>&nbsp;premarket on modest volume.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283310\" data-linked=\"NXT-ID announces preliminary Q2 and 1H results; shares ahead 23% premarket\" data-tweet=\"$NXTD - NXT-ID announces preliminary Q2 and 1H results; shares ahead 23% premarket https://seekingalpha.com/news/3283310-nxt-id-announces-preliminary-q2-and-1h-results-shares-ahead-23-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3283310-nxt-id-announces-preliminary-q2-and-1h-results-shares-ahead-23-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283305\" data-ts=\"1501505794\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYO\" target=\"_blank\">MYO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283305-myomos-powered-arm-brace-ce-markd-shares-ahead-19-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Myomo&#39;s powered arm brace CE Mark&#39;d; shares ahead 19% premarket</a></h4><ul><li>Thinly traded nano cap Myomo (NYSEMKT:<a href='https://seekingalpha.com/symbol/MYO' title='Myomo, Inc.'>MYO</a>) is up&nbsp;<font color='green'>19%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16900750-myomo-inc-obtains-ce-mark-approval-myopro\" target=\"_blank\">announcement </a>that its MyoPro myoelectric arm orthosis is now CE Mark certified.</li><li><a href=\"http://myomo.com/what-is-a-myopro-orthosis/\" target=\"_blank\">MyoPro </a>is wearable device that restores function in paralyzed or weakened arms and hands in patients who have suffered an injury or stroke. It was launched commercially in June.</li></ul><div class=\"tiny-share-widget\" data-id=\"3283305\" data-linked=\"Myomo&#39;s powered arm brace CE Mark&#39;d; shares ahead 19% premarket\" data-tweet=\"$MYO - Myomo&#39;s powered arm brace CE Mark&#39;d; shares ahead 19% premarket https://seekingalpha.com/news/3283305-myomos-powered-arm-brace-ce-markd-shares-ahead-19-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3283305-myomos-powered-arm-brace-ce-markd-shares-ahead-19-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283300\" data-ts=\"1501505240\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/F\" target=\"_blank\">F</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283300-austin-pd-sidelines-ford-police-interceptors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Austin PD sidelines Ford Police Interceptors</a></h4><ul> <li>The Austin Police Department <a href=\"http://www.fox7austin.com/news/local-news/271007264-story\" target=\"_blank\">removes</a>&nbsp;all Ford (NYSE:<a href='https://seekingalpha.com/symbol/F' title='Ford Motor Company'>F</a>) Police Interceptors from its fleet due to a large number of carbon monoxide complaints.</li> <li>\"Unfortunately the number and the severity of the cases has continued to grow,\" says Austin Interim City Manager Elaine Hart. \"I&rsquo;ve made the decision that we need to remove these vehicles from service immediately,\" she adds.</li> <li>The APD's action sidelines almost 400 Ford Explorers, representing 61% of the department's patrol fleet.</li> <li>Ford says it will cover some of the police interceptor repair bills, although the company notes that modifications may have lead to the issue.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3282913-ford-explorer-exhaust-fume-probe-expands\" target=\"_blank\">Ford Explorer exhaust fume probe expands</a> (July 28)</li><li>Shares of Ford are&nbsp;<font color='red'>down 0.36%</font>&nbsp;premarket to $11.13.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3283300\" data-linked=\"Austin PD sidelines Ford Police Interceptors\" data-tweet=\"$F - Austin PD sidelines Ford Police Interceptors https://seekingalpha.com/news/3283300-austin-pd-sidelines-ford-police-interceptors?source=tweet\" data-url=\"https://seekingalpha.com/news/3283300-austin-pd-sidelines-ford-police-interceptors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283266\" data-ts=\"1501501680\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ULTA\" target=\"_blank\">ULTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283266-ulta-beauty-on-watch-after-oppenheimer-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ulta Beauty on watch after Oppenheimer downgrade</a></h4><ul> <li>Oppenheimer downgrades Ulta Beauty (NASDAQ:<a href='https://seekingalpha.com/symbol/ULTA' title='Ulta Beauty, Inc.'>ULTA</a>) to Market Perform after having the cosmetics seller rated at Outperform.</li> <li>A negative stance from L'Oreal on the U.S. market is a factor in the Oppy action as well as ongoing discounting in the department store sector. \"We now view the backdrop as more challenging for Ulta to deliver the same level of comp and earnings upside investors have grown accustomed to,\" reads the analyst note.</li><li>The firm lowers it <a href=\"http://www.marketwatch.com/story/ulta-beauty-downgraded-on-sector-weakness-in-the-us-2017-07-31\" target=\"_blank\">price target</a> on Ulta to $270 from $330.</li> <li>ULTA <font color='red'>-0.45%</font> premarket to $247.47.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283266\" data-linked=\"Ulta Beauty on watch after Oppenheimer downgrade\" data-tweet=\"$ULTA - Ulta Beauty on watch after Oppenheimer downgrade https://seekingalpha.com/news/3283266-ulta-beauty-on-watch-after-oppenheimer-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3283266-ulta-beauty-on-watch-after-oppenheimer-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283265\" data-ts=\"1501501459\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMY\" target=\"_blank\">BMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283265-bristol-myers-and-clovis-to-evaluate-opdivo-rubraca-combo-in-range-of-tumors-clovis-down-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bristol-Myers and Clovis to evaluate Opdivo/Rubraca combo in range of tumors; Clovis down 6% premarket</a></h4><ul><li>Bristol-Myers Squibb (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>) and Clovis Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a>) ink a clinical collaboration <a href=\"https://seekingalpha.com/pr/16900602-bristol-myers-squibb-clovis-oncology-announce-broad-clinical-collaboration-evaluate\" target=\"_blank\">agreement </a>to evaluate the combination of PD-1 inhibitor Opdivo (nivolumab) and PARP inhibitor Rubraca (rucaparib) across multiple tumor types.</li><li>Phase 3 studies will be conducted in advanced ovarian cancer and advanced triple-negative breast cancer. The partnership will also include a Phase 2 clinical trial in metastatic castration-resistant prostate cancer.</li><li>Clovis will sponsor and run the ovarian cancer trial while Bristol-Myers will be responsible for the prostate cancer and breast cancer studies. All three should commence before year-end.</li><li>CLVS is down&nbsp;<font color='red'>6%</font>&nbsp;premarket on modestly higher volume. Shares rallied over&nbsp;<font color='green'>15%</font>&nbsp;last week as investors were anticipating good news, possibly a buyout.</li></ul><div class=\"tiny-share-widget\" data-id=\"3283265\" data-linked=\"Bristol-Myers and Clovis to evaluate Opdivo/Rubraca combo in range of tumors; Clovis down 6% premarket\" data-tweet=\"$BMY $BMY $CLVS - Bristol-Myers and Clovis to evaluate Opdivo/Rubraca combo in range of tumors; Clovis down 6% premarket https://seekingalpha.com/news/3283265-bristol-myers-and-clovis-to-evaluate-opdivo-rubraca-combo-in-range-of-tumors-clovis-down-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3283265-bristol-myers-and-clovis-to-evaluate-opdivo-rubraca-combo-in-range-of-tumors-clovis-down-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283255\" data-ts=\"1501500605\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRX\" target=\"_blank\">AMRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283255-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Impax Labs (IPXL) initiated with Hold rating by Canaccord Genuity citing valuation.</li><li>Celgene (NASDAQ:<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a>) upgraded to Buy from Hold by Argus Research.</li><li>Dynavax (NASDAQ:<a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a>) upgraded to Overweight from Neutral by JPMorgan. Upgraded to Outperform with a $26 (181% upside) price target by RBC Capital Markets. Shares are up&nbsp;<font color='green'>103%</font>&nbsp;premarket on robust volume after Friday's positive Ad Com vote on HEPLISAV-B.</li><li>athenahealth (NASDAQ:<a href='https://seekingalpha.com/symbol/ATHN' title='athenahealth, Inc.'>ATHN</a>) downgraded to Market Perform from Outperform by Cowen and Company.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3283255\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$AMRX $AMRX $CELG - Premarket analyst action - healthcare https://seekingalpha.com/news/3283255-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3283255-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283253\" data-ts=\"1501500377\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SOGO\" target=\"_blank\">SOGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283253-sohu-com-beats-revenue-estimates-issues-strong-guidance-sharesplus-7_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sohu.com beats revenue estimates, issues strong guidance; shares +7.5%</a></h4><ul><li>Sohu.com (NASDAQ:<a href='https://seekingalpha.com/symbol/SOHU' title='Sohu.com Inc.'>SOHU</a>) with a revenue beat and an EPS miss. Brand advertising revenues were down 24% on the year to $86M with the weakness attributed to video ad sales..&nbsp;Online game revenues were up 23% to $122M. Search and search-related ad revenues were up 17% to $187M.</li><li>Gross margin was 40% overall, 19% for the online ad business, -45% for the brand advertising business, 48% for search and search-related ads, and 91% for online games.</li><li>Operating expenses totaled $223M and the company ended the quarter with $1.24B in cash and equivalents.</li><li>Q3 outlook: revenues between $480M and $510M and loss per share between $1 and $1.25. Consensus estimates have revenue at $474.62 and a loss per share of $1.17.</li><li><a href=\"https://seekingalpha.com/pr/16900489-sohu-com-reports-second-quarter-2017-unaudited-financial-results\" target=\"_blank\">Press release</a></li><li>Sohu.com shares are&nbsp;<font color='green'>up 7.47%</font>&nbsp;premarket.</li><li>Update: Sohu.com also <a href=\"http://investors.sohu.com/releasedetail.cfm?ReleaseID=1034998\" target=\"_blank\">announces </a>plans for subsidiary Sogou to file for an IPO. Sogou revenues were up 20% on the year to $211M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3283253\" data-linked=\"Sohu.com beats revenue estimates, issues strong guidance; shares +7.5%\" data-tweet=\"$SOGO $SOHU - Sohu.com beats revenue estimates, issues strong guidance; shares +7.5% https://seekingalpha.com/news/3283253-sohu-com-beats-revenue-estimates-issues-strong-guidance-sharesplus-7_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3283253-sohu-com-beats-revenue-estimates-issues-strong-guidance-sharesplus-7_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283252\" data-ts=\"1501500233\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283252-analysts-update-on-tesla-after-model-3-event\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts update on Tesla after Model 3 event</a></h4><ul> <li>KeyBanc Capital Markets calls Tesla's (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) report of +500K reservations on the Model 3 the \"most important metric and basis for the stock\" into the trading week. Analyst Brad Erickson sees short-term positive momentum for shares of Tesla ahead of the company's earnings report on Wednesday. On the cautious side, Erickson notes that the \"all-in\" high-range Model 3 isn't quite at a mass market price ($58K) and warns on plateauing Model S and Model X demand.</li>   <li>\"Initial reviews have been encouraging; more importantly, however, the vehicle could be more profitable and easier to manufacture than anticipated, placing Tesla&rsquo;s threat to incumbent (manufacturers) in ever sharper focus,\" observes Berenberg Bank analyst Alexander Haissl.</li> <li>Baird remains locked in at Outperform on Tesla due to the long-term potential, but thinks shares will dip after the Q2 numbers are spilled.</li> <li>Source: Bloomberg and <a href=\"https://www.forbes.com/sites/neilwinton/2017/07/31/tesla-model-3-excites-launch-event-but-also-promises-fat-profits/#69ab1dfb4a76\" target=\"_blank\">Forbes.com</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3283155-spotlight-falls-tesla-model-3\" target=\"_blank\">The spotlight falls on the Tesla Model 3</a> (July 29)</li> <li>Shares of Tesla are <font color='green'>up 1.47%</font> premarket to $340.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3283252\" data-linked=\"Analysts update on Tesla after Model 3 event\" data-tweet=\"$TSLA - Analysts update on Tesla after Model 3 event https://seekingalpha.com/news/3283252-analysts-update-on-tesla-after-model-3-event?source=tweet\" data-url=\"https://seekingalpha.com/news/3283252-analysts-update-on-tesla-after-model-3-event\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>202&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283249\" data-ts=\"1501500098\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICPT\" target=\"_blank\">ICPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283249-intercept-pharma-net-loss-widens-in-q2-shares-ahead-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intercept Pharma net loss widens in Q2; shares ahead 3% premarket</a></h4><ul><li>Intercept Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a>) <a href=\"https://seekingalpha.com/pr/16900669-intercept-pharmaceuticals-reports-second-quarter-2017-financial-results-provides-business\" target=\"_blank\">Q2 results</a>: Revenues: $30.9M; Operating Loss: ($80.5M) (-3.1%); Net Loss: ($86.6M) (-12.0%); Loss Per Share: ($3.46) (-10.2%); Quick Assets: $550.3M (-20.2%).</li><li><strong>2017 Guidance</strong>: Non-GAAP Operating Expenses: $380M - 420M (unch).</li><li>Shares are up&nbsp;<font color='green'>3%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3283249\" data-linked=\"Intercept Pharma net loss widens in Q2; shares ahead 3% premarket\" data-tweet=\"$ICPT - Intercept Pharma net loss widens in Q2; shares ahead 3% premarket https://seekingalpha.com/news/3283249-intercept-pharma-net-loss-widens-in-q2-shares-ahead-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3283249-intercept-pharma-net-loss-widens-in-q2-shares-ahead-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283237\" data-ts=\"1501499026\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNY\" target=\"_blank\">SNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283237-sanofi-q2-revenues-up-4-non-gaap-eps-up-3-shares-ahead-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sanofi Q2 revenues up 4%; non-GAAP EPS up 3%; shares ahead 2% premarket</a></h4><ul><li>Sanofi (<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a> <font color='red'>-1.1%</font>) <a href=\"http://mediaroom.sanofi.com/sanofi-raises-fy-2017-business-eps1-guidance-to-broadly-stable-at-cer2/\" target=\"_blank\">Q2 results</a>&nbsp;(&euro;): Revenues: 8,663M (+6.4%); Sanofi Genzyme (Specialty Care): 1,439M (+14.3%); Diabetes and Cardiovascular: 1,386M (+15.0%); General Medicines &amp; Emerging Markets: 3,659M (-1.2%);Consumer Healthcare: 1,163M (+42.5%); Sanofi Pasteur (Vaccines): 1,016M (+26.2%).</li><li>Operating Income: 1,375M (-4.2%); Net Income: 1,037M (-10.4%); EPS: 0.82 (-8.9%); Non-GAAP EPS: 1.35 (+3.1%); Quick Assets: 10,877M (+5.9%).</li><li>Key product sales: Lantus: 1,197M (-19.2%); Lovenox: 402M (-2.4%); Plavix: 385M (-0.3%); Aubagio: 425M (+32.7%); Renvela/Renagel: 248M (+16.8%); Toujeo: 210M (+46.1%); Myozyme/Lumizyme: 203M (+10.4%); Cerezyme: 193M (-2.0%); Fabrazyme: 190M (+12.0%).</li><li><strong>2017 Guidance</strong>: Earnings -3% on constant currency basis.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3283237\" data-linked=\"Sanofi Q2 revenues up 4%; non-GAAP EPS up 3%; shares ahead 2% premarket\" data-tweet=\"$SNY - Sanofi Q2 revenues up 4%; non-GAAP EPS up 3%; shares ahead 2% premarket https://seekingalpha.com/news/3283237-sanofi-q2-revenues-up-4-non-gaap-eps-up-3-shares-ahead-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3283237-sanofi-q2-revenues-up-4-non-gaap-eps-up-3-shares-ahead-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283204\" data-ts=\"1501494727\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNY\" target=\"_blank\">SNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283204-sanofi-reports-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sanofi reports Q2 results</a></h4><ul><li>Sanofi (NASDAQ:<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a>): Q2 EPS of&nbsp;&euro;1.35</li><li>Revenue of&nbsp;&euro;8.66B (+6.4% Y/Y)</li><li>Shares <font color='green'>+2.61%</font> PM.</li><li><a href=\"http://mediaroom.sanofi.com/sanofi-raises-fy-2017-business-eps1-guidance-to-broadly-stable-at-cer2/\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3283204\" data-linked=\"Sanofi reports Q2 results\" data-tweet=\"$SNY - Sanofi reports Q2 results https://seekingalpha.com/news/3283204-sanofi-reports-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3283204-sanofi-reports-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283202\" data-ts=\"1501494350\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HSBC\" target=\"_blank\">HSBC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283202-hsbc-holdings-reports-1h-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HSBC Holdings reports 1H results</a></h4><ul><li>HSBC Holdings (NYSE:<a href='https://seekingalpha.com/symbol/HSBC' title='HSBC Holdings PLC'>HSBC</a>): 1H EPS of $0.35</li><li>Revenue of $26.17B (-11.2% Y/Y)</li><li>Shares <font color='green'>+2.49%</font> PM.</li><li><a href='http://www.hsbc.com/investor-relations/group-results-and-reporting'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3283202\" data-linked=\"HSBC Holdings reports 1H results\" data-tweet=\"$HSBC - HSBC Holdings reports 1H results https://seekingalpha.com/news/3283202-hsbc-holdings-reports-1h-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3283202-hsbc-holdings-reports-1h-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3283192\" data-ts=\"1501492195\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFTBY\" target=\"_blank\">SFTBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3283192-softbank-closes-in-on-charter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Softbank closes in on Charter</a></h4><ul><li>Masayoshi Son plans to <a href=\"https://www.bloomberg.com/news/articles/2017-07-31/softbank-s-son-is-said-to-plan-direct-offer-for-charter\" target=\"_blank\">use</a> SoftBank (<a href='https://seekingalpha.com/symbol/SFTBY' title='SoftBank Group ADR'>OTCPK:SFTBY</a>) in a direct bid for Charter Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/CHTR' title='Charter Communications, Inc.'>CHTR</a>) after an earlier merger proposal by its U.S. wireless unit, Sprint (NYSE:<a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a>), was rejected.</li><li>According to Bloomberg, Son plans to make the offer this week ahead of a public announcement, which could reignite deal talks that had <a href=\"https://seekingalpha.com/news/3283169-wsj-charter-sprint-deal\" target=\"_blank\">appeared</a> to be dead as of late Sunday.</li><li>CHTR <font color='green'>+5.3%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3283192\" data-linked=\"Softbank closes in on Charter\" data-tweet=\"$SFTBY $SFTBY $CHTR - Softbank closes in on Charter https://seekingalpha.com/news/3283192-softbank-closes-in-on-charter?source=tweet\" data-url=\"https://seekingalpha.com/news/3283192-softbank-closes-in-on-charter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":73,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}